School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
    • Contact Us
  • Education
    • Degree and Certificate Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory

Directory section navigation

  • Faculty Profiles

Emory University School of Medicine

  • About
    • Sub link
      Our Vision
    • Sub link
      Academic Departments
    • Sub link
      Our Leadership
    • Sub link
      Health Care Partnerships
    • Sub link
      Diversity, Equity, & Inclusion
    • Sub link
      Location
    • Sub link
      Supporting Our People
    • Sub link
      Our Faculty
    • Sub link
      History
    • Sub link
      News
    • Sub link
      Events
    • Sub link
      Contact Us
  • Education
    • Sub link
      Degree and Certificate Programs
    • Sub link
      Academic Departments
    • Sub link
      Residents & Fellows
    • Sub link
      Postdoctoral Training
    • Sub link
      Continuing Medical Education
    • Sub link
      Admissions
    • Sub link
      Cost and Financial Aid
    • Sub link
      Student Resources
  • Research
    • Sub link
      Research Innovation
    • Sub link
      Conducting Research
    • Sub link
      Core Facilities
    • Sub link
      Research Centers
    • Sub link
      Research Training
    • Sub link
      Academic Departments
    • Sub link
      Find a Researcher
    • Sub link
      Research News
  • Clinical Experience
    • Sub link
      Where We Work
    • Sub link
      Caring for a Diverse Population
    • Sub link
      Faculty Clinical Experience
    • Sub link
      Advanced Patient Care
    • Sub link
      Academic Departments
    • Sub link
      Community Learning
  • Giving
  • Directory
  • Home School of Medicine Home
  • Directory

Profile

Bassel El-Rayes MD

  • Winship Cancer Institute
    Center Member, Winship
  • (404) 778-1900
  • bassel.el-rayes@emoryhealthcare.org

Academic Appointment

  • Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine

Education

Degrees

  • MD from American University of Beirut
  • BS from American University of Beirut

Research

Focus

  • My research is on translational projects related to gastrointestinal malignancies, specifically pancreatic and colorectal cancer, to bring observations derived from in vitro models of cancer cell growth to the clinic. I closely collaborate with basic scientists in studies that target the HSP90, NF-kB cell signaling pathways such as HDAC-6 in pancreatic cancer cells.

Publications

  • Paricalcitol plus hydroxychloroquine enhances gemcitabine activity and induces mesenchymal to epithelial transition in pancreatic ductal adenocarcinoma: A single cell RNA-seq analysis.
    Cancer Lett Volume: 625 Page(s): 217809
    08/10/2025 Authors: Nagaraju GP; Saddala MS; Sarvesh S; Bandi DSR; Khaliq AM; Masood A; Akce M; El-Rayes BF
  • A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer.
    Cancer Res Volume: 85 Page(s): 956 - 972
    03/03/2025 Authors: Foote JB; Mattox TE; Keeton AB; Chen X; Smith FT; Berry K; Holmes TW; Wang J; Huang C-H; Ward A
  • Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations.
    JCO Oncol Adv Volume: 2 Page(s): e2400032
    01/01/2025 Authors: Azar I; Khan HY; Bannoura SF; Gandhi N; Uddin MH; Nagasaka M; Gong J; Nazha B; Choucair K; Vojjala N
  • RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth.
    Cancer Lett Volume: 604 Page(s): 217275
    11/01/2024 Authors: Bannoura SF; Aboukameel A; Khan HY; Uddin MH; Jang H; Beal EW; Thangasamy A; Shi Y; Kim S; Wagner K-U
  • Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.
    Ann Oncol Volume: 35 Page(s): 537 - 548
    06/01/2024 Authors: Melero I; Yau T; Kang Y-K; Kim T-Y; Santoro A; Sangro B; Kudo M; Hou M-M; Matilla A; Tovoli F
  • Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
    Mol Cancer Ther Volume: 22 Page(s): 1422 - 1433
    12/01/2023 Authors: Khan HY; Nagasaka M; Aboukameel A; Alkhalili O; Uddin MH; Bannoura SF; Mzannar Y; Azar I; Beal EW; Tobon ME
  • DNA-PK is activated by SIRT2 deacetylation to promote DNA double-strand break repair by non-homologous end joining.
    Nucleic Acids Res Volume: 51 Page(s): 7972 - 7987
    08/25/2023 Authors: Head PE; Kapoor-Vazirani P; Nagaraju GP; Zhang H; Rath SK; Luong NC; Haji-Seyed-Javadi R; Sesay F; Wang S-Y; Duong DM
  • Time to treatment initiation and its impact on real-world survival in metastatic colorectal cancer and pancreatic cancer.
    Cancer Med Volume: 12 Page(s): 3488 - 3498
    02/01/2023 Authors: Gbolahan O; Hashemi-Sadraei N; Yash S; Williams G; Ramachandran R; Kim Y-I; Paluri R; Outlaw D; El-Rayes B; Nabell L
  • Epigenetics in hepatocellular carcinoma.
    Semin Cancer Biol Volume: 86 Page(s): 622 - 632
    11/01/2022 Authors: Nagaraju GP; Dariya B; Kasa P; Peela S; El-Rayes BF
  • Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma.
    Nat Commun Volume: 13 Page(s): 6418
    10/27/2022 Authors: Ravindranathan S; Passang T; Li J-M; Wang S; Dhamsania R; Ware MB; Zaidi MY; Zhu J; Cardenas M; Liu Y
  • Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer.
    Clin Cancer Res Volume: 28 Page(s): 4336 - 4345
    10/03/2022 Authors: Ruggieri AN; Yarchoan M; Goyal S; Liu Y; Sharon E; Chen HX; Olson BM; Paulos CM; El-Rayes BF; Maithel SK
  • Role of local therapy in the management of patients with metastatic anal squamous cell carcinoma: a National Cancer Database study.
    J Gastrointest Oncol Volume: 13 Page(s): 2306 - 2321
    10/01/2022 Authors: Atallah RP; Zhang Y; Zakka K; Jiang R; Huang Z; Shaib WL; Diab M; Akce M; Wu C; El-Rayes BF
  • Epidemiology of early esophageal adenocarcinoma.
    Clin Endosc Volume: 55 Page(s): 372 - 380
    05/01/2022 Authors: Hang T-VP; Spiritos Z; Gamboa AM; Chen Z; Force S; Patel V; Chawla S; Keilin S; Saba NF; El-Rayes B
  • Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers.
    Cancers (Basel) Volume: 14
    03/29/2022 Authors: Kang S; El-Rayes BF; Akce M
  • Correlates of financial toxicity in adult cancer patients and their informal caregivers.
    Support Care Cancer Volume: 30 Page(s): 217 - 225
    01/01/2022 Authors: Sadigh G; Switchenko J; Weaver KE; Elchoufi D; Meisel J; Bilen MA; Lawson D; Cella D; El-Rayes B; Carlos R
  • Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
    Oncol Res Treat Volume: 45 Page(s): 430 - 437
    01/01/2022 Authors: Kang S; Magliocca J; Sellers M; Roccaro G; Zheng W; Pectasides M; Draper A; Guadagno J; El-Rayes B; Akce M
  • Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
    Oncology Volume: 100 Page(s): 131 - 139
    01/01/2022 Authors: Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
  • A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186.
    Cancer Immunol Immunother Volume: 70 Page(s): 3337 - 3348
    11/01/2021 Authors: Herting CJ; Farren MR; Tong Y; Liu Z; O'Neil B; Bekaii-Saab T; Noonan A; McQuinn C; Mace TA; Shaib W
  • Negative enrichment of circulating tumor cells from unmanipulated whole blood with a 3D printed device.
    Sci Rep Volume: 11 Page(s): 20583
    10/18/2021 Authors: Chu C-H; Liu R; Ozkaya-Ahmadov T; Swain BE; Boya M; El-Rayes B; Akce M; Bilen MA; Kucuk O; Sarioglu AF
  • PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.
    Mol Cancer Ther Volume: 20 Page(s): 1836 - 1845
    10/01/2021 Authors: Mpilla GB; Uddin MH; Al-Hallak MN; Aboukameel A; Li Y; Kim SH; Beydoun R; Dyson G; Baloglu E; Senapedis WT
  • Targeting KRAS in pancreatic cancer: new drugs on the horizon.
    Cancer Metastasis Rev Volume: 40 Page(s): 819 - 835
    09/01/2021 Authors: Bannoura SF; Uddin MH; Nagasaka M; Fazili F; Al-Hallak MN; Philip PA; El-Rayes B; Azmi AS
  • CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
    J Hepatol Volume: 75 Page(s): 600 - 609
    09/01/2021 Authors: Kudo M; Matilla A; Santoro A; Melero I; Gracin AC; Acosta-Rivera M; Choo S-P; El-Khoueiry AB; Kuromatsu R; El-Rayes B
  • Crosstalk Between Cancer Associated Fibroblast Soluble Mediators and Pancreatic Cancer Cells Facilitate an Invasive Phenotype
    Volume: 50 Page(s): 1061 - 1061
    08/01/2021 Authors: Greene E; Ware M; Herting C; Maithel S; Sarmiento J; El-Rayes BF; Tucker-Burden C; Marcus A; Lesinski GB
  • PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus
    Volume: 50 Page(s): 1105 - 1105
    08/01/2021 Authors: Uddin M; Mpilla G; Al-Hallak MN; Aboukameel A; Li Y; Kim S; Beydoun R; Dyson G; Baloglu E; Senapedis W
  • Vasoactive Intestinal Peptide Receptor Signaling: A Novel and Targetable Immune Checkpoint Pathway in Pancreatic Cancer
    Volume: 50 Page(s): 1091 - 1092
    08/01/2021 Authors: Ravindranathan S; Tenzin P; Ware M; Zaidi M; Wang S; Dhamsania R; Zhu J; Liu Y; Liu Y; Gumber S
  • Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer.
    Oncologist Volume: 26 Page(s): 668 - 675
    08/01/2021 Authors: Sahin IH; Goyal S; Pumpalova Y; Sonbol MB; Das S; Haraldsdottir S; Ahn D; Ciombor KK; Chen Z; Draper A
  • A phase I trial of trifluridine/tipiracil in combination with nanoliposomal irinotecan in advanced GI cancers
    Volume: 32 Page(s): S200 - S200
    07/03/2021 Authors: Alese O; Shaib W; Akce M; Diab M; Issa-Boube M; Ekundayo F; Wu C; El-Rayes B
  • Checkmate 040 Cohort 5: long-term efficacy and safety of nivolumab in patients with Child-Pugh B advanced hepatocellular carcinoma: associations between baseline biomarker analyses and outcomes
    Volume: 75 Page(s): S243 - S244
    07/01/2021 Authors: Matilla A; Sangro B; El-Khoureiry A; Santoro A; Melero I; Gracian AC; Rivera MA; Choo S-P; Kuromatsu R; El-Rayes B
  • Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review.
    Clin Colorectal Cancer Volume: 20 Page(s): 153 - 160
    06/01/2021 Authors: Bryson E; Sakach E; Patel U; Watson M; Hall K; Draper A; Davis C; Goyal S; Alese O; Akce M
  • Survival Outcomes of Acinar Cell Pancreatic Cancer: A National Cancer Database Analysis.
    Pancreas Volume: 50 Page(s): 529 - 536
    04/01/2021 Authors: Shaib WL; Zakka K; Huang W; Chen Z; Alese OB; Wu C; Akce M; El-Rayes BF
  • Preliminary Safety, PK/PD, and Antitumor Activity of XmAb18087, an SSTR2 x CD3 Bispecific Antibody, in Patients With Advanced Neuroendocrine Tumors
    Volume: 50 Page(s): 445 - 446
    03/01/2021 Authors: El-Rayes B; Pant S; Villalobos V; Hendifar A; Chow W; Konda B; Reilley M; Benson A; Fisher G; Starr J
  • Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid/goblet cell adenocarcinoma of the appendix?
    Surg Oncol Volume: 36 Page(s): 120 - 129
    03/01/2021 Authors: Zakka K; Williamson S; Jiang R; Reid MD; Alese OB; Shaib WL; Wu C; Behera M; El-Rayes BF; Akce M
  • Perioperative therapy in metastatic colorectal cancer: Pattern of use and survival outcomes.
    J Surg Oncol Volume: 123 Page(s): 596 - 605
    02/01/2021 Authors: Alese OB; Zakka K; Huo X; Jiang R; Shaib WL; Akce M; Behera M; Sullivan P; Wu C; El-Rayes BF
  • Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody.
    Am J Clin Oncol Volume: 44 Page(s): 74 - 81
    02/01/2021 Authors: Akce M; Liu Y; Zakka K; Martini DJ; Draper A; Alese OB; Shaib WL; Wu C; Wedd JP; Sellers MT
  • Should Signet Ring Cell Histology Alter the Treatment Approach for Clinical Stage I Gastric Cancer?
    Ann Surg Oncol Volume: 28 Page(s): 97 - 105
    01/01/2021 Authors: Turgeon MK; Gamboa AC; Rupji M; Lee RM; Switchenko JM; El-Rayes BF; Russell MC; Cardona K; Kooby DA; Staley CA
  • Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival.
    Front Oncol Volume: 11 Page(s): 728076
    01/01/2021 Authors: Alese OB; Zhou W; Jiang R; Zakka K; Huang Z; Okoli C; Shaib WL; Akce M; Diab M; Wu C
  • High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer.
    Front Oncol Volume: 11 Page(s): 755113
    01/01/2021 Authors: Mohamed A; Jiang R; Philip PA; Diab M; Behera M; Wu C; Alese O; Shaib WL; Gaines TM; Balch GG
  • Impact of high-risk features for stage II adenocarcinoma of the appendix.
    Volume: 27 Page(s): 100329
    01/01/2021 Authors: Akce M; Zakka K; Penley M; Jiang R; Khalil L; Alese OB; Shaib WL; Wu C; Behera M; El-Rayes BF
  • Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status.
    Volume: 11 Page(s): 592351
    01/01/2021 Authors: Akce M; Zakka K; Jiang R; Williamson S; Alese OB; Shaib WL; Wu C; Behera M; El-Rayes BF
  • Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer.
    Mol Cancer Ther Volume: 20 Page(s): 150 - 160
    01/01/2021 Authors: Zhang Y; Ware MB; Zaidi MY; Ruggieri AN; Olson BM; Komar H; Farren MR; Nagaraju GP; Zhang C; Chen Z
  • Variant anatomy of the biliary system as a cause of pancreatic and peri-ampullary cancers.
    HPB (Oxford) Volume: 22 Page(s): 1675 - 1685
    12/01/2020 Authors: Muraki T; Reid MD; Pehlivanoglu B; Gonzalez RS; Sekhar A; Memis B; Xue Y; Cheng J; Jang K-T; Mittal P
  • HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Surg Oncol Volume: 35 Page(s): 460 - 465
    12/01/2020 Authors: Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA
  • Orbital and Ocular Metastasis from Neuroendocrine Tumors: A Case Series
    Volume: 113 Page(s): 673 - 673
    12/01/2020 Authors: Zakka KM; Shaib W; Kucuk K; Wheeler S; Bergstrom C; El-Rayes B
  • Lymph Node Subcapsular Sinus Microenvironment-On-A-ChipModeling Shear Flow Relevant to Lymphatic Metastasis and Immune Cell Homing.
    iScience Volume: 23 Page(s): 101751
    11/20/2020 Authors: Birmingham KG; O'Melia MJ; Bordy S; Reyes Aguilar D; El-Reyas B; Lesinski G; Thomas SN
  • INVESTIGATING THE CLINICAL SAFETY, EFFICACY, AND IMMUNE MODULATION OF COMBINED XL888 AND PEMBROLIZUMAB IN METASTATIC GASTROINTESTINAL MALIGNANCIES
    Volume: 8 Page(s): A202 - A203
    11/01/2020 Authors: Herting C; Zhang Y; Doxie D; Farren M; Ware M; Alese O; Wu C; Shaib W; Akce M; Zaidi M
  • Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
    JAMA Oncol Volume: 6 Page(s): e204564
    11/01/2020 Authors: Yau T; Kang Y-K; Kim T-Y; El-Khoueiry AB; Santoro A; Sangro B; Melero I; Kudo M; Hou M-M; Matilla A
  • Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated.
    Cancer Volume: 126 Page(s): 4788 - 4799
    11/01/2020 Authors: Xue Y; Balci S; Aydin Mericoz C; Taskin OC; Jiang H; Pehlivanoglu B; Muraki T; Memis B; Saka B; Kim GE
  • Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease.
    Br J Cancer Volume: 123 Page(s): 1377 - 1386
    10/01/2020 Authors: Ware MB; Zaidi MY; Yang J; Turgeon MK; Krasinskas A; Mace TA; Keenan K; Farren MR; Ruggieri AN; Li Y
  • Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.
    Br J Cancer Volume: 123 Page(s): 1228 - 1234
    10/01/2020 Authors: Harvey RD; Carthon BC; Lewis C; Hossain MS; Zhang C; Chen Z; Harris WB; Alese OB; Shaib W; Bilen MA
  • Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer.
    Cancer Volume: 126 Page(s): 4136 - 4147
    09/15/2020 Authors: Shaib WL; Zakka KM; Jiang R; Yan M; Alese OB; Akce M; Wu C; Behera M; El-Rayes BF
  • Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification.
    Endocr Pathol Volume: 31 Page(s): 239 - 253
    09/01/2020 Authors: Xue Y; Reid MD; Pehlivanoglu B; Obeng RC; Jiang H; Memis B; Lui SK; Sarmiento J; Kooby D; Maithel SK
  • Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer.
    J Immunother Cancer Volume: 8
    08/01/2020 Authors: Ware MB; El-Rayes BF; Lesinski GB
  • Turning up the heat on pancreatic ductal adenocarcinoma via inhibiting vasoactive intestinal peptide signaling
    Volume: 80
    08/01/2020 Authors: Ravindranathan S; Ware B; Zaidi M; Zhu J; Dhamsania RK; Wang S; Li Y; Rao IH; Thomas SN; Lesinski GB
  • Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations.
    World J Gastroenterol Volume: 26 Page(s): 4036 - 4054
    07/28/2020 Authors: Mpilla GB; Philip PA; El-Rayes B; Azmi AS
  • Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer.
    Cancer Volume: 126 Page(s): 3360 - 3371
    07/15/2020 Authors: Nagaraju GP; Farran B; Farren M; Chalikonda G; Wu C; Lesinski GB; El-Rayes BF
  • Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer.
    Pancreas Volume: 49 Page(s): 822 - 829
    07/01/2020 Authors: Shaib WL; Zakka K; Shahin AA; Yared F; Switchenko JM; Wu C; Akce M; Alese OB; Patel PR; Mcdonald M
  • A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.
    Clin Cancer Res Volume: 26 Page(s): 2497 - 2505
    06/01/2020 Authors: Owonikoko TK; Harvey RD; Carthon B; Chen Z; Lewis C; Collins H; Zhang C; Lawson DH; Alese OB; Bilen MA
  • Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs.
    JCO Oncol Pract Volume: 16 Page(s): 319 - 325
    06/01/2020 Authors: Sahin IH; Kane SR; Brutcher E; Guadagno J; Smith KE; Wu C; Lesinski GB; Gunthel CJ; El-Rayes BF
  • Adjuvant concurrent chemoradiotherapy in extrahepatic cholangiocarcinoma.
    Volume: 38
    05/20/2020 Authors: Shaib WL; Zakka KM; Tian F; Chen Z; Patel PR; Lin JY; Wu C; Akce M; Alese OB; El-Rayes BF
  • Blood-based next-generation sequencing analysis of neuroendocrine neoplasms.
    Oncotarget Volume: 11 Page(s): 1749 - 1757
    05/12/2020 Authors: Zakka K; Nagy R; Drusbosky L; Akce M; Wu C; Alese OB; El-Rayes BF; Kasi PM; Mody K; Starr J
  • In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy.
    J Geriatr Oncol Volume: 11 Page(s): 660 - 667
    05/01/2020 Authors: Shaib WL; Zakka K; Hoodbhoy FN; Belalcazar A; Kim S; Cardona K; Russell MC; Maithel SK; Sarmiento JM; Wu C
  • High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study.
    Oncologist Volume: 25 Page(s): e877
    05/01/2020 Authors: Alese OB; Jiang R; Shaib W; Wu C; Akce M; Behera M; El-Rayes BF
  • Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers.
    Oncologist Volume: 25 Page(s): 414 - 421
    05/01/2020 Authors: Shaib WL; Zakka K; Staley C; Roberts A; Akce M; Wu C; Alese OB; El-Rayes BF
  • STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?
    J Gastrointest Surg Volume: 24 Page(s): 1138 - 1148
    05/01/2020 Authors: Lopez-Aguiar AG; Postlewait LM; Ethun CG; Zaidi MY; Zhelnin K; Krasinskas A; Russell MC; Kooby DA; Cardona K; El-Rayes BF
  • Young Adults With Pancreatic Cancer: National Trends in Treatment and Outcomes.
    Pancreas Volume: 49 Page(s): 341 - 354
    03/01/2020 Authors: Alese OB; Jiang R; Shaib W; Wu C; Akce M; Gaines T; Ni L; Behera M; El-Rayes BF
  • Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
    Oncologist Volume: 25 Page(s): e528 - e535
    03/01/2020 Authors: Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H
  • Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials.
    Cancer Volume: 126 Page(s): 575 - 582
    02/01/2020 Authors: Martini DJ; Kline MR; Liu Y; Shabto JM; Williams MA; Khan AI; Lewis C; Collins H; Akce M; Kissick HT
  • Clinicopathological features and survival outcomes of rare histologic variants of gallbladder cancer.
    J Surg Oncol Volume: 121 Page(s): 294 - 302
    02/01/2020 Authors: Akce M; Zakka K; Penley M; Jiang R; Alese OB; Shaib WL; Wu C; Behera M; El-Rayes BF
  • The impact of inflammatory biomarkers, BMI, and sarcopenia on survival in advanced hepatocellular carcinoma treated with immunotherapy
    Volume: 38
    02/01/2020 Authors: Akce M; Liu Y; Zakka KM; Martini DJ; Draper A; Alese OB; Shaib WL; Wu C; Wedd J; Sellers MT
  • Clinical and molecular markers of immune checkpoint inhibitor (ICI) response in dMMR colorectal cancer (CRC) patients (pts)
    Volume: 38
    02/01/2020 Authors: Sahin IH; Goyal S; Pumpalova YS; Sonbol MB; Das S; Haraldsdottir S; Chen Z; Akce M; Alese OB; Shaib WL
  • Is adjuvant chemotherapy beneficial for stage II-III goblet cell tumors of the appendix?
    Volume: 38
    02/01/2020 Authors: Zakka KM; Williamson S; Jiang R; Alese OB; Shaib WL; Wu C; Behera M; El-Rayes BF; Akce M
  • Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy.
    JCI Insight Volume: 5
    01/16/2020 Authors: Farren MR; Sayegh L; Ware MB; Chen H-R; Gong J; Liang Y; Krasinskas A; Maithel SK; Zaidi M; Sarmiento JM
  • Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy.
    Cancer Volume: 126 Page(s): 37 - 45
    01/01/2020 Authors: Tian S; Jiang R; Madden NA; Ferris MJ; Buchwald ZS; Xu KM; Cardona K; Maithel SK; McDonald MW; Lin JY
  • Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma.
    Front Oncol Volume: 10 Page(s): 1632
    01/01/2020 Authors: Chinnadurai R; Scandolara R; Alese OB; Arafat D; Ravindranathan D; Farris AB; El-Rayes BF; Gibson G
  • Handbook of Gastrointestinal Cancers Evidence-Based Treatment and Multidisciplinary Patient Care Preface
    Page(s): XVII - XVII
    01/01/2020 Authors: Bekaii-Saab T; El-Rayes BF; Pawlik TM
  • Nonbacterial Thrombotic Endocarditis and Widespread Skin Necrosis in Newly Diagnosed Lung Adenocarcinoma.
    Case Rep Oncol Volume: 13 Page(s): 239 - 244
    01/01/2020 Authors: Zakka K; Zakka P; Davarpanah A; Koshkelashvili N; Bilen MA; Owonikoko T; El-Rayes B; Akce M
  • Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
    Oncologist
    12/05/2019 Authors: Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H
  • IL-6 regulates CTLA4 expression on CD4+T-cells and dual antibody blockade of IL-6 and CTLA4 leads to tumor regression in an orthotopic murine model of pancreatic ductal adenocarcinoma
    Volume: 79
    12/01/2019 Authors: Ware MB; McQuinn C; Mace TA; Bowers J; Shakya R; Farris B; Young G; Carson WE; Paulos CM; El-Rayes B
  • Pancreatic stellate cells promote pancreatic cancer invasion and metastasis by secretion of soluble factors and through contact-mediated mechanisms
    Volume: 79
    12/01/2019 Authors: Ware MB; Yue J; El-Rayes B; Maithel SK; Sarmiento J; Lesinski GB
  • Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.
    Invest New Drugs Volume: 37 Page(s): 1198 - 1206
    12/01/2019 Authors: Martini DJ; Liu Y; Shabto JM; Lewis C; Kline MR; Collins H; Akce M; Kissick HT; Carthon BC; Shaib WL
  • Analysis of racial disparities in the treatment and outcomes of colorectal cancer in young adults.
    Cancer Epidemiol Volume: 63 Page(s): 101618
    12/01/2019 Authors: Alese OB; Jiang R; Zakka KM; Wu C; Shaib W; Akce M; Behera M; El-Rayes BF
  • Clinical Outcomes of Small Bowel Adenocarcinoma.
    Volume: 18 Page(s): 257 - 268
    12/01/2019 Authors: Akce M; Jiang R; Zakka K; Wu C; Alese OB; Shaib WL; Behera M; El-Rayes BF
  • PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors.
    Cancers (Basel) Volume: 11
    11/29/2019 Authors: Mpilla G; Aboukameel A; Muqbil I; Kim S; Beydoun R; Philip PA; Mohammad RM; Kamgar M; Shidham V; Senapedis W
  • Vasoactive intestinal peptide: a novel checkpoint pathway in pancreatic ductal adenocarcinoma
    Volume: 7
    11/06/2019 Authors: Ravindranathan S; Wang S; Ware B; Zaidi M; Zhu J; Dhamsania R; Thomas S; Li Y; El-rayes B; Lesinski G
  • Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
    Oncologist Volume: 24 Page(s): 1453 - 1461
    11/01/2019 Authors: Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz H-J; Atasoy A; Shangguan T; Zhao H; El-Rayes B
  • A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.
    Br J Clin Pharmacol Volume: 85 Page(s): 2499 - 2511
    11/01/2019 Authors: Takebe N; Beumer JH; Kummar S; Kiesel BF; Dowlati A; O'Sullivan Coyne G; Piekarz R; Rubinstein L; Fogli LK; Vaishampayan U
  • Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms.
    Br J Cancer Volume: 121 Page(s): 809 - 818
    11/01/2019 Authors: Sahin IH; Akce M; Alese O; Shaib W; Lesinski GB; El-Rayes B; Wu C
  • CHECKMATE 040: EFFICACY, HEPATIC SAFETY, AND BIOMARKERS OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
    Volume: 70 Page(s): 131A - 132A
    10/01/2019 Authors: Sangro B; Hsu C; Kang Y-K; Kim T-Y; El-Khoueiry A; Santoro A; Melero I; Kudo M; Hou M-M; Pena AM
  • Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic metastasis of pancreatobiliary origin.
    J Gastrointest Oncol Volume: 10 Page(s): 944 - 956
    10/01/2019 Authors: Nezami N; Camacho JC; Kokabi N; El-Rayes BF; Kim HS
  • Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer.
    Int J Cancer Volume: 145 Page(s): 1529 - 1537
    09/15/2019 Authors: Nagaraju GP; Zakka KM; Landry JC; Shaib WL; Lesinski GB; El-Rayes BF
  • Effect of Neoadjuvant SBRT or Chemoradiation on Nodal Positivity for Resected Pancreatic Adenocarcinoma
    Volume: 105 Page(s): E237 - E238
    09/01/2019 Authors: Jiang C; Rupji M; Goyal S; Liu Y; Tanenbaum DG; Xu KM; Shaib W; El-rayes B; Sarmiento J; Maithel SK
  • The Effect of Neoadjuvant Radiotherapy on Tumor Regression Grade in Resected Pancreatic Adenocarcinoma
    Volume: 105 Page(s): E241 - E242
    09/01/2019 Authors: Patel PR; Jiang C; Xu KM; Tanenbaum DG; Rupji M; Krasinskas A; El-rayes B; Shaib W; Alese O; Sarmiento J
  • Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
    BMC Cancer Volume: 19 Page(s): 857
    08/29/2019 Authors: Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL
  • National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer.
    Cancer Volume: 125 Page(s): 2732 - 2746
    08/15/2019 Authors: George TJ; Franke AJ; Chakravarthy AB; Das P; Dasari A; El-Rayes BF; Hong TS; Kinsella TJ; Landry JC; Lee JJ
  • Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
    J Natl Cancer Inst Volume: 111 Page(s): 782 - 794
    08/01/2019 Authors: Janssen QP; Buettner S; Suker M; Beumer BR; Addeo P; Bachellier P; Bahary N; Bekaii-Saab T; Bali MA; Besselink MG
  • Induction Therapy in Localized Pancreatic Cancer.
    Pancreas Volume: 48 Page(s): 913 - 919
    08/01/2019 Authors: Shaib WL; Sayegh L; Zhang C; Belalcazar A; Ip A; Alese OB; Akce M; Wu C; Qu Y; Maithel SK
  • High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study.
    Oncologist Volume: 24 Page(s): 911 - 920
    07/01/2019 Authors: Alese OB; Jiang R; Shaib W; Wu C; Akce M; Behera M; El-Rayes BF
  • Targeting vasoactive intestinal peptide signaling to enhance pancreatic cancer responsiveness to immunotherapy
    Volume: 79
    07/01/2019 Authors: Ravindranathan S; Li Y; Wang S; Zaidi MY; Lesinski GB; El-Rayes B; Waller EK
  • DNA-PKCS deacetylation by SIRT2 promotes DNA double-strand break repair by non-homologous end joining
    CANCER RESEARCH Volume: 79
    07/01/2019 Authors: Head PE; Ganji NP; Wang S-Y; Duong D; Zhang H; Daddacha W; Li S; Seyfried NT; Smalley DM; Wang Y
  • Targeted hyaluronic acid nanoparticles improve treatment response in pancreatic cancer
    Volume: 79
    07/01/2019 Authors: Jajja MR; Zhu L; Wang D; Staley CA; El-Rayes B; Kooby DA; Yang L
  • Comparison of neoadjuvant FOLFIRINOX alone vs FOLFIRINOX plus stereotactic body radiation as immune-modulators of the pancreatic adenocarcinoma microenvironment
    Volume: 79
    07/01/2019 Authors: Farren MR; Shaib W; Zaidi M; Sayegh L; Kooby D; Maithel S; Krasinskas A; Alese O; Sarmiento J; El-Rayes B
  • Heat shock protein 90 inhibitors alter pancreatic stellate cell cytokine production and enhances the efficacy of immune checkpoint blockade in pancreatic cancer
    Volume: 79
    07/01/2019 Authors: Zaidi M; Zhang Y; Ware MB; Farren MR; Komar H; Olson B; Nagaraju GP; Akce M; Alese O; Maithel S
  • BBI-608 modulates DNA repair pathways, induces apoptosis and impacts response to 5-Fluorouracil and ionizing radiation in pancreatic cancer cells
    Volume: 79
    07/01/2019 Authors: Farran B; Nagaraju GP; Shipra SG; Bethi SR; Lesinski GB; El-Rayes B
  • BBI-608 enhances the activity of chemoradiotherapy in colorectal cancer pre-clinical models
    Volume: 79
    07/01/2019 Authors: Nagaraju GP; Balney R; Bethi SR; Govardhanagiri S; Lesinski GBLB; El-Rayes BF
  • Interaction of STAT proteins with genistein: A computational analysis
    Volume: 79
    07/01/2019 Authors: Govardhanagiri S; Bethi SR; Saddala MS; El-Rayes BF; Nagaraju GP
  • Curcumin analogs: Their roles in pancreatic cancer growth and metastasis.
    Int J Cancer Volume: 145 Page(s): 10 - 19
    07/01/2019 Authors: Nagaraju GP; Benton L; Bethi SR; Shoji M; El-Rayes BF
  • Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
    J Gastrointest Cancer Volume: 50 Page(s): 269 - 275
    06/01/2019 Authors: Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
  • Derazantinib (DZB) provides antitumor efficacy regardless of line of therapy in patients (pts) with FGFR2-fusion positive advanced intrahepatic cholangiocarcinoma (iCCA).
    Volume: 37
    05/20/2019 Authors: Busset MDD; El-Rayes BF; Harris WP; Damjanov N; Masi G; Rimassa L; Bhoori S; Niger M; Personeni N; Braiteh FS
  • Personalized T cell therapy for metastatic colon cancer.
    Volume: 37
    05/20/2019 Authors: Ravindranathan S; Jajja MR; Waller A; Bommireddy R; Petersen C; Selvaraj P; Yang L; Lesinski GB; El-Rayes BF; Flynn B
  • Blood-based next-generation sequencing analysis of neuroendocrine tumors.
    Volume: 37
    05/20/2019 Authors: Shaib WL; Roberts A; Zakka KM; Akce M; Wu C; Alese OB; El-Rayes BF; Kasi PM; Starr JS
  • Perioperative therapy in patients with metastatic colorectal cancer.
    Volume: 37
    05/20/2019 Authors: Alese OB; Zakka KM; Huo X; Jiang R; Shaib WL; Wu C; Akce M; Sullivan PS; Behera M; El-Rayes BF
  • Vasoactive intestinal peptide signaling - a novel immune checkpoint in pancreatic ductal adenocarcinoma
    Volume: 202
    05/01/2019 Authors: Ravindranathan S; Li Y; Wang S; Zaidi M; Lesinski GB; El-Rayes B; Waller EK
  • Cyclooxygenase-2 in gastrointestinal malignancies.
    Cancer Volume: 125 Page(s): 1221 - 1227
    04/15/2019 Authors: Nagaraju GP; El-Rayes BF
  • Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040
    Volume: 70 Page(s): E619 - E619
    04/01/2019 Authors: Sangro B; Matilla AM; Santoro A; Melero I; Cubillo Gracian A; Rivera Acosta M; Choo S-P; El-Khoureiry A; Kuromatsu R; El-Rayes B
  • Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer.
    Am J Clin Oncol Volume: 42 Page(s): 331 - 336
    04/01/2019 Authors: Saba NF; Force S; Staley C; Fernandez F; Willingham F; Pickens A; Cardona K; Chen Z; Goff L; Cardin D
  • Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.
    J Gastrointest Cancer Volume: 50 Page(s): 1 - 8
    03/01/2019 Authors: Tan E; El-Rayes B
  • Autotaxin determines colitis severity in mice and is secreted by B cells in the colon.
    FASEB J Volume: 33 Page(s): 3623 - 3635
    03/01/2019 Authors: Lin S; Haque A; Raeman R; Guo L; He P; Denning TL; El-Rayes B; Moolenaar WH; Yun CC
  • Nonsurgical Management of Rectal Cancer.
    J Oncol Pract Volume: 15 Page(s): 123 - 131
    03/01/2019 Authors: Akce M; El-Rayes BF
  • Clinical outcomes of hepatocellular carcinoma variants compared to hepatocellular carcinoma.
    Volume: 37
    02/01/2019 Authors: Zakka KM; Jiang R; Alese OB; Shaib WL; Wu C; Wedd J; Sellers MT; Behera M; El-Rayes BF; Akce M
  • Genomic alterations in appendiceal carcinoma using circulating DNA.
    Volume: 37
    02/01/2019 Authors: Shaib WL; Roberts A; Akce M; Wu C; Alese OB; El-Rayes BF
  • Impact of genomic alterations (GAs) on outcomes and their distribution by age groups in metastatic colorectal cancer (mCRC) patients (pts)
    Volume: 37
    02/01/2019 Authors: Sahin IH; Chen WH; Chen Z; Akce M; Alese OB; Shaib WL; El-Rayes BF; Wu C
  • Phase II randomized, double-blind, study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients hcrn GI14-198.
    Volume: 37
    02/01/2019 Authors: Shaib WL; O'Neil B; El-Rayes BF; Cohen SJ; Khair TA; Robin EL; Huyck TK; Redman RA; Sama AR; Kassar M
  • Sequential immunotherapy and association with clinical outcomes in advanced-stage cancer patients
    Volume: 7
    02/01/2019 Authors: Bilen M; Martini D; Liu Y; Lewis C; Collins H; Shabto J; Akce M; Kissick H; Carthon B; Shaib W
  • Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis.
    J Gastrointest Oncol Volume: 10 Page(s): 85 - 94
    02/01/2019 Authors: Akce M; Jiang R; Alese OB; Shaib WL; Wu C; Behera M; El-Rayes BF
  • Tumor Penetrating Polymeric Nanoparticle Improves Response in a Drug Resistant Pancreatic Cancer PDX Model
    Volume: 26 Page(s): S6 - S7
    02/01/2019 Authors: Jajja M; Zhu L; Wang D; Staley C; El-Rayes B; Kooby DA; Yang L
  • TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial.
    JMIR Res Protoc Volume: 8 Page(s): e11545
    01/17/2019 Authors: Chauhan N; Mulcahy MF; Salem R; Benson Iii AB; Boucher E; Bukovcan J; Cosgrove D; Laframboise C; Lewandowski RJ; Master F
  • Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.
    Br J Cancer Volume: 120 Page(s): 165 - 171
    01/01/2019 Authors: Mazzaferro V; El-Rayes BF; Droz Dit Busset M; Cotsoglou C; Harris WP; Damjanov N; Masi G; Rimassa L; Personeni N; Braiteh F
  • Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma.
    J Hepatocell Carcinoma Volume: 6 Page(s): 119 - 129
    01/01/2019 Authors: Zakka K; Jiang R; Alese OB; Shaib WL; Wu C; Wedd JP; Sellers MT; Behera M; El-Rayes BF; Akce M
  • Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer.
    Cancer Volume: 125 Page(s): 57 - 67
    01/01/2019 Authors: Shaib WL; Narayan AS; Switchenko JM; Kane SR; Wu C; Akce M; Alese OB; Patel PR; Maithel SK; Sarmiento JM
  • Racial Disparities, Outcomes, and Surgical Utilization among Hispanics with Esophageal Cancer: A Surveillance, Epidemiology, and End Results Program Database Analysis.
    Oncology Volume: 97 Page(s): 49 - 58
    01/01/2019 Authors: Gupta DR; Liu Y; Jiang R; Walid S; Higgins K; Landry J; McDonald M; Willingham FF; El-Rayes BF; Saba NF
  • The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.
    Cancer Volume: 125 Page(s): 127 - 134
    01/01/2019 Authors: Bilen MA; Martini DJ; Liu Y; Lewis C; Collins HH; Shabto JM; Akce M; Kissick HT; Carthon BC; Shaib WL
  • Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles.
    Mol Cancer Volume: 17 Page(s): 177
    12/21/2018 Authors: Imperial R; Ahmed Z; Toor OM; Erdoan C; Khaliq A; Case P; Case J; Kennedy K; Cummings LS; Melton N
  • Nivolumab in Patients with Child-Pugh B Advanced Hepatocellular Carcinoma (aHCC) in the CheckMate-040 Study
    Volume: 68 Page(s): 1445A - 1446A
    12/01/2018 Authors: Kudo M; Matilla AM; Santoro A; Melero I; Cubillo Gracian A; Rivera Acosta M; Choo SP; El-Khoueiry A; Kuromatsu R; El Rayes B
  • Pilot Study of Potential Activation of c-MYC by Aurora Kinase A in Everolimus-Resistant Localized Esophageal Cancer Treated with XELOX followed by Carboplatin/Radiation
    Volume: 102 Page(s): E27 - E27
    11/01/2018 Authors: Saba NF; Force S; Staley CA; Fernandez F; Willingham FF; Pickens A; Cardona K; Chen Z; Goff L; Cardin D
  • Apoptosis-Inducing Effect of Erlotinib Is Potentiated by 3,3 '-Diindolylmethane In Vitro and In Vivo Using an Orthotopic Model of Pancreatic Cancer (Retraction of Vol 7, Pg 1708, 2008)
    MOLECULAR CANCER THERAPEUTICS Volume: 17 Page(s): 2266 - 2266
    10/01/2018 Authors: Ali S; Banerjee S; Ahmad A; El-Rayes BF; Philip PA; Sarkar FH
  • Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO).
    Volume: 29 Suppl 8 Page(s): viii42
    10/01/2018 Authors: Bilen MA; Martini DJ; Shabto JM; Liu Y; Khan AI; Williams MA; Lewis C; Collins HH; Kissick H; Carthon BC
  • The Epidemiology of Esophageal Adenocarcinoma in the United States
    Volume: 113 Page(s): S185 - S186
    10/01/2018 Authors: Hang T-VP; Spiritos Z; Gamboa A; Chen Z; Force S; Keilin S; Saba N; El-Rayes B; Cai Q; Willingham F
  • Potentiation of the Effect of Erlotinib by Genistein in Pancreatic Cancer: The Role of Akt and Nuclear Factor-kappa B (Retraction of Vol 66, Pg 10553, 2006)
    CANCER RESEARCH Volume: 78 Page(s): 5472 - 5472
    09/15/2018 Authors: El-Rayes BF; Philip PA; Abbruzzese J; Sarkar FH; Ali S; Ali IF
  • Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
    Cancer Volume: 124 Page(s): 3118 - 3126
    08/01/2018 Authors: Sanoff HK; Goldberg RM; Ivanova A; O'Reilly S; Kasbari SS; Kim RD; McDermott R; Moore DT; Zamboni W; Grogan W
  • Blood based biomarkers and association with clinical outcome (CO) in advanced stage patients (pts) treated with immunotherapy (IO)
    Volume: 78
    07/01/2018 Authors: Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Pillai R
  • Derazantinib (ARQ 087) pharmacodynamics: Alterations in FGF19/21/23 and phosphate in patients with cholangiocarcinoma
    Volume: 78
    07/01/2018 Authors: Hall T; Mazzaferro V; El-Rayes B; Cotsoglou C; Harris WP; Damjanov N; Masi G; Rimassa L; Personeni N; Zagonel V
  • Inhibition of Hsp90 sensitizes pancreatic cancer in vitro and in vivo to chemo-radiotherapy
    Volume: 78
    07/01/2018 Authors: Nagaraju GP; El-Rayes BF
  • Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis.
    Oncologist Volume: 23 Page(s): 704 - 711
    06/01/2018 Authors: Shaib WL; Jones JS; Goodman M; Sarmiento JM; Maithel SK; Cardona K; Kane S; Wu C; Alese OB; El-Rayes BF
  • Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer.
    Crit Rev Oncol Hematol Volume: 126 Page(s): 201 - 207
    06/01/2018 Authors: Hurtado M; Sankpal UT; Ranjan A; Maram R; Vishwanatha JK; Nagaraju GP; El-Rayes BF; Basha R
  • A Phase II multi institutional study of nivolumab in patients with advanced refractory biliary tract cancers (BTC).
    Volume: 29 Suppl 5 Page(s): v103
    06/01/2018 Authors: Kim R; Kim D; Alese O; Li D; El-Rayes B; Shah N; Schell M; Zhou J; Chung V
  • Survival outcomes in gastric and gastroesophageal junction adenocarcinoma treated with peri-operative chemotherapy with or without pre-operative radiotherapy.
    Volume: 36
    05/20/2018 Authors: Tian S; Jiang R; Madden NA; Ferris MJ; Buchwald Z; Xu KM; Cardona K; Maithel S; McDonald MW; Lin JY
  • Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.
    Volume: 36
    05/20/2018 Authors: Janssen Q; Buettner S; Suker M; Margonis GA; Paniccia A; El-Rayes BF; Bahary N; Chau I; Hosein PJ; Ko AH
  • Adjuvant treatment for resected sub-centimeter T1 pancreatic cancer.
    Volume: 36
    05/20/2018 Authors: Shaib WL; Naranyan AS; Switchenko JM; Akce M; Sarmiento J; Maithel S; Kooby DA; Patel PR; Cardona K; Alese OB
  • Early change in blood-based biomarkers and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO)
    Volume: 36
    05/20/2018 Authors: Martini DJ; Liu Y; Lewis CM; Shabto JM; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Pillai RN
  • A phase I/II study of trifluridine/tipiracil (TAS-102) in combination with nanoliposomal irinotecan (NAL-IRI) in advanced GI cancers.
    Volume: 36
    05/20/2018 Authors: Alese OB; Shaib WL; Akce M; Wu C; El-Rayes BF
  • Incidence, treatment and survival outcomes of small bowel adenocarcinomas: A National Cancer Database (NCDB) analysis.
    Volume: 36
    05/20/2018 Authors: Akce M; Jiang R; Wu C; Alese OB; Shaib WL; Behera M; El-Rayes BF
  • Retrospective study of the safety of administering pegfilgrastim on the same day of 5-Fluorouracil pump disconnect.
    Volume: 36
    05/20/2018 Authors: Patel N; Wu C; Draper A; LaFollette JA; Brutcher E; El-Rayes BF; Alese OB; Shaib WL; Akce M; Chen Z
  • Impact of adjuvant chemotherapy in higher risk stage II colon cancer with a deficient mismatch repair (dMMR)/ microsatellite instability-high (MSI-H) profile.
    Volume: 36
    05/20/2018 Authors: Mohamed AMR; Jiang R; Philip PA; Diab M; Behera M; Wu C; El-Rayes BF; Akce M
  • Altering the cytokine profile in the pancreatic cancer microenvironment with heat shock protein-90 inhibitors to enhance immunotherapy.
    Volume: 200
    05/01/2018 Authors: Lesinski GB; Zhang Y; Farren MR; Komar H; Ware B; Olson B; Zaidi M; Nagaraju GP; Akce M; Alese OB
  • A patient-centered team approach in oncology.
    Cancer Volume: 124 Page(s): 1856 - 1858
    05/01/2018 Authors: Wu CS; El-Rayes BF
  • Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.
    Cancer Volume: 124 Page(s): 1992 - 2000
    05/01/2018 Authors: Kim HS; Shaib WL; Zhang C; Nagaraju GP; Wu C; Alese OB; Chen Z; Brutcher E; Renfroe M; El-Rayes BF
  • Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer.
    Cancer Chemother Pharmacol Volume: 81 Page(s): 659 - 670
    04/01/2018 Authors: El-Khoueiry AB; Sarantopoulos J; O'Bryant CL; Ciombor KK; Xu H; O'Gorman M; Chakrabarti J; Usari T; El-Rayes BF
  • Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer.
    Ann Surg Oncol Volume: 25 Page(s): 1026 - 1033
    04/01/2018 Authors: Zhong J; Switchenko J; Behera M; Kooby D; Maithel SK; McDonald MW; Lin JY; Cassidy RJ; El-Rayes B; Landry J
  • Adenocarcinoma Ex-Goblet Cell Carcinoid Is Not aNeuroendocrine Neoplasm: Immunoprofiling of 60 Cases Further Establishes Its Identity As a Distinct (Appendiceal Type) of Adenocarcinoma
    Volume: 98 Page(s): 297 - 297
    03/01/2018 Authors: Reid M; Pehlivanoglu B; Xue Y; Memis B; Robinson B; Toussaint MA; Krasinskas A; Staley C; El-Rayes B; Mogal H
  • Adenocarcinoma Ex-Goblet Cell Carcinoid Is Not aNeuroendocrine Neoplasm: Immunoprofiling of 60 Cases Further Establishes Its Identity As a Distinct (Appendiceal Type) of Adenocarcinoma
    Volume: 31 Page(s): 297 - 297
    03/01/2018 Authors: Reid M; Pehlivanoglu B; Xue Y; Memis B; Robinson B; Toussaint MA; Krasinskas A; Staley C; El-Rayes B; Mogal H
  • Growth Pattern Of Invasive Ampullary Carcinomas As Demarcated Versus Infitlrative Has Significant Prognostic Correlation; A Clinicopathologic Analysis Of 257 Cases
    Volume: 31 Page(s): 313 - 314
    03/01/2018 Authors: Xue Y; Pehlivanoglu B; Reid M; Krasinskas A; Balci S; Kim G; Davis D; Liu H; Peng L; Tajiri T
  • Low Union (Lower Insertion of Cystic Duct into Common Hepatic Duct) as a Major Etiologic Factor in the Development of Pancreatic, Distal Bile Duct and Ampullary Cancers: An analysis of 860 pancreatobiliary resections
    Volume: 31 Page(s): 684 - 685
    03/01/2018 Authors: Muraki T; Reid M; Gonzalez RS; Sekhar A; Memis B; Pehlivanoglu B; Xue Y; Mittal P; Sarmiento JM; Kooby D
  • Low Union (Lower Insertion of Cystic Duct into Common Hepatic Duct) as a Major Etiologic Factor in the Development of Pancreatic, Distal Bile Duct and Ampullary Cancers: An analysis of 860 pancreatobiliary resections
    Volume: 98 Page(s): 684 - 685
    03/01/2018 Authors: Muraki T; Reid M; Gonzalez RS; Sekhar A; Memis B; Pehlivanoglu B; Xue Y; Mittal P; Sarmiento JM; Kooby D
  • Growth Pattern Of Invasive Ampullary Carcinomas As Demarcated Versus Infitlrative Has Significant Prognostic Correlation; A Clinicopathologic Analysis Of 257 Cases
    Volume: 98 Page(s): 313 - 314
    03/01/2018 Authors: Xue Y; Pehlivanoglu B; Reid M; Krasinskas A; Balci S; Kim G; Davis D; Liu H; Peng L; Tajiri T
  • STAT3 inhibition for gastroenteropancreatic neuroendocrine tumors: Potential for a new therapeutic target?
    Volume: 36
    02/01/2018 Authors: Lopez-Aguiar AG; Postlewait LM; Zaidi M; Zhelnin K; Krasinskas A; Russell MC; Kooby DA; Cardona K; El-Rayes BF; Maithel S
  • Resection of pancreatic cancer following induction chemotherapy.
    Volume: 36
    02/01/2018 Authors: Shaib WL; Sayegh L; Alese O; Maithel S; Cardona K; Sarmiento J; Belalcazar A; Ip A; Qu Y; Akce M
  • Epidemiology and treatment of high-grade gastrointestinal neuroendocrine tumors (HG-GI-NETs)
    Volume: 36
    02/01/2018 Authors: Alese OB; Jiang R; Shaib WL; Wu CS-Y; Akce M; Behera M; El-Rayes BF
  • Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies.
    Volume: 36
    02/01/2018 Authors: Akce M; Alese OB; Shaib WL; Wu CS-Y; Lesinski GB; El-Rayes BF
  • The Potential of CAR T Cell Therapy in Pancreatic Cancer.
    Front Immunol Volume: 9 Page(s): 2166
    01/01/2018 Authors: Akce M; Zaidi MY; Waller EK; El-Rayes BF; Lesinski GB
  • Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials.
    Oncology Volume: 95 Page(s): 138 - 146
    01/01/2018 Authors: Owonikoko TK; Busari AK; Kim S; Chen Z; Akintayo A; Lewis C; Carthon BC; Alese OB; El-Rayes BF; Ramalingam SS
  • Appendiceal Mucinous Neoplasms: Diagnosis and Management.
    Oncologist Volume: 23 Page(s): 137
    01/01/2018 Authors: Shaib WL; Assi R; Shamseddine A; Alese OB; Staley C; Memis B; Adsay V; Bekaii-Saab T; El-Rayes BF
  • Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
    Ann Surg Oncol Volume: 25 Page(s): 290 - 298
    01/01/2018 Authors: Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA
  • Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells.
    Cancer Volume: 123 Page(s): 4924 - 4933
    12/15/2017 Authors: Belalcazar A; Shaib WL; Farren MR; Zhang C; Chen Z; Yang L; Lesinski GB; El-Rayes BF; Nagaraju GP
  • Incidence and Survival of Appendiceal Mucinous Neoplasms: A SEER Analysis.
    Am J Clin Oncol Volume: 40 Page(s): 569 - 573
    12/01/2017 Authors: Shaib WL; Goodman M; Chen Z; Kim S; Brutcher E; Bekaii-Saab T; El-Rayes BF
  • A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.
    Br J Cancer Volume: 117 Page(s): 1592 - 1599
    11/21/2017 Authors: Papadopoulos KP; El-Rayes BF; Tolcher AW; Patnaik A; Rasco DW; Harvey RD; LoRusso PM; Sachdev JC; Abbadessa G; Savage RE
  • Combined IL-6 and CTLA4 blockade enhances CD8+T cell infiltration via CXCR3 and limits growth of pancreatic cancer in murine models
    Volume: 5
    11/07/2017 Authors: McQuinn C; Farren M; Mace T; Bowers J; Shakya R; Ferris AB; Young G; Carson W; Paulos C; El-Rayes B
  • Optimal Treatment Phase Selection Based on a 4DCT Deformable Registration for Stereotactic Body Radiation Therapy in Pancreatic Cancer
    Volume: 99 Page(s): E743 - E743
    10/01/2017 Authors: Yang X; Wang T; Liu T; Zhu L; Khan MK; El-Rayes B; Curran WJ; Landry JC
  • Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base.
    Cancer Volume: 123 Page(s): 3476 - 3485
    09/15/2017 Authors: Naik KB; Liu Y; Goodman M; Gillespie TW; Pickens A; Force SD; Steuer CE; Owonikoko TK; Ramalingam SS; Higgins K
  • Long-Term Survival in Stage IV Esophageal Adenocarcinoma with Chemoradiation and Serial Endoscopic Cryoablation.
    Clin Endosc Volume: 50 Page(s): 491 - 494
    09/01/2017 Authors: Spiritos Z; Mekaroonkamol P; El-Rayes BF; Force SD; Keilin SA; Cai Q; Willingham FF
  • Appendiceal Mucinous Neoplasms: Diagnosis and Management.
    Oncologist Volume: 22 Page(s): 1107 - 1116
    09/01/2017 Authors: Shaib WL; Assi R; Shamseddine A; Alese OB; Staley C; Memis B; Adsay V; Bekaii-Saab T; El-Rayes BF
  • Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer.
    Cancer Lett Volume: 402 Page(s): 110 - 116
    08/28/2017 Authors: Nagaraju GP; Wu C; Merchant N; Chen Z; Lesinski GB; El-Rayes BF
  • LBA-002A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts).
    Ann Oncol Volume: 28
    06/01/2017 Authors: Bekaii-Saab T; Starodub A; El-Rayes B; O'Neil B; Shahda S; Ciombor K; Noonan A; Hanna W; Sehdev A; Shaib W
  • A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts).
    Volume: 28 Suppl 3 Page(s): iii150
    06/01/2017 Authors: Bekaii-Saab T; Starodub A; El-Rayes B; O'Neil B; Shahda S; Ciombor K; Noonan A; Hanna W; Sehdev A; Shaib W
  • ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations.
    Volume: 35
    05/20/2017 Authors: Mazzaferro V; El-Rayes BF; Cotsoglou C; Harris WP; Damjanov N; Masi G; Rimassa L; Personeni N; Braiteh FS; Zagonel V
  • Safety and pharmacokinetics of crizotinib in patients (pts) with hepatic impairment (HI) and advanced cancer.
    Volume: 35
    05/20/2017 Authors: EI-Khoueiry AB; Sarantopoulos J; O'Bryant CL; Ciombor KK; Xu H; O'Gorman MT; Chakrabarti J; Usari T; El-Rayes BF
  • Safety of trifluridine/tipiracil for metastatic colorectal cancer in African American patients participating in an expanded access program.
    Volume: 35
    05/20/2017 Authors: Philip PA; Smaglo BG; El-Rayes BF; Lesuisse C; Makris L
  • A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer.
    Volume: 35
    05/20/2017 Authors: Shanda S; Noonan AM; Bekaii-Saab TS; O'Neil BH; Sehdev A; Shaib WL; Helft PR; Loehrer PJ; Tong Y; Liu Z
  • Chemotherapy with or without definitive radiation therapy in locally advanced pancreatic cancer.
    Volume: 35
    05/20/2017 Authors: Zhong J; Switchenko JM; Behera M; Kooby DA; McDonald MW; El-Rayes BF; Landry JC; Patel PR
  • Enrollment into molecular selection trials and impact on patient disposition.
    Volume: 35
    05/20/2017 Authors: Harvey RD; Steuer CE; Judson EC; Lewis CM; Collins HH; Saba NF; El-Rayes BF; Curran WJ; Rannalingam SS; Pentz RD
  • Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer (EC).
    Volume: 35
    05/20/2017 Authors: Saba NF; Force SD; Staley CA; Fernandez FG; Willingham FF; Allan P; Cardona K; Chen Z; Cardin DB; Lambright E
  • Treatment, outcomes, and impact of racial disparities on young adults with pancreatic cancer.
    Volume: 35
    05/20/2017 Authors: Alese OB; Jiang R; Shaib WL; Wu CS-Y; Behera M; El-Rayes BF
  • Racial disparities in treatment and outcomes of colorectal cancer in young adults.
    Volume: 35
    05/20/2017 Authors: Alese OB; Jiang R; Shaib WL; Wu CS-Y; Behera M; El-Rayes BF
  • Identifying and targeting cancer stem cells in the treatment of gastric cancer.
    Cancer Volume: 123 Page(s): 1303 - 1312
    04/15/2017 Authors: Bekaii-Saab T; El-Rayes B
  • Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).
    J Clin Oncol Volume: 35 Page(s): 718 - 726
    03/01/2017 Authors: Garg MK; Zhao F; Sparano JA; Palefsky J; Whittington R; Mitchell EP; Mulcahy MF; Armstrong KI; Nabbout NH; Kalnicki S
  • Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy.
    Cancer Lett Volume: 388 Page(s): 139 - 148
    03/01/2017 Authors: Zhu L; Staley C; Kooby D; El-Rays B; Mao H; Yang L
  • Adenocarcinoma Ex-Goblet Cell Carcinoid of the Appendix Is a Tumor of Intestinal Lineage and Mucinous Differentiation
    Volume: 30 Page(s): 196A - 196A
    02/01/2017 Authors: Robinson B; Memis B; Toussaint A; Xue Y; Krasinskas A; Staley C; Winer JH; Russell MC; Shaib W; El-Rayes B
  • Adenocarcinoma Ex-Goblet Cell Carcinoid of the Appendix Is a Tumor of Intestinal Lineage and Mucinous Differentiation
    Volume: 97 Page(s): 196A - 196A
    02/01/2017 Authors: Robinson B; Memis B; Toussaint A; Xue Y; Krasinskas A; Staley C; Wino JH; Russell MC; Shaib W; El-Rayes B
  • HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for novel therapeutic targets.
    Volume: 35
    02/01/2017 Authors: Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K
  • HSP90 Expression and Early Recurrence in Gastroenteropancreatic Neuroendocrine Tumors: Potential for Novel Therapeutic Targets
    Volume: 24 Page(s): S97 - S97
    02/01/2017 Authors: Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes B; Russell M; Kooby D; Staley CA; Cardona K
  • Non-ampullary-duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas.
    Mod Pathol Volume: 30 Page(s): 255 - 266
    02/01/2017 Authors: Xue Y; Vanoli A; Balci S; Reid MM; Saka B; Bagci P; Memis B; Choi H; Ohike N; Tajiri T
  • Establishment of human metastatic colorectal cancer model in rabbit liver: A pilot study.
    PLoS One Volume: 12 Page(s): e0177212
    01/01/2017 Authors: Prieto V; Ludwig JM; Farris AB; Nagaraju GP; Lawal TO; El-Rayes B; Kim HS
  • Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
    Cancer Volume: 123 Page(s): 345 - 356
    01/01/2017 Authors: Ma WW; Saif MW; El-Rayes BF; Fakih MG; Cartwright TH; Posey JA; King TR; von Borstel RW; Bamat MK
  • Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor.
    Oncology Volume: 93 Page(s): 336 - 342
    01/01/2017 Authors: Evans M; Liu Y; Chen C; Steuer C; Cassidy R; Landry J; Higgins K; Beitler JJ; Willingham F; Owonikoko TK
  • Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer.
    Mol Carcinog Volume: 56 Page(s): 288 - 299
    01/01/2017 Authors: Rajitha B; Nagaraju GP; Shaib WL; Alese OB; Snyder JP; Shoji M; Pattnaik S; Alam A; El-Rayes BF
  • An update on the multimodality of localized rectal cancer.
    Crit Rev Oncol Hematol Volume: 108 Page(s): 23 - 32
    12/01/2016 Authors: Artac M; Korkmaz L; El-Rayes B; Philip PA
  • Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors.
    Target Oncol Volume: 11 Page(s): 807 - 814
    12/01/2016 Authors: Mita MM; Nemunaitis J; Grilley-Olson J; El-Rayes B; Bekaii-Saab T; Harvey RD; Marshall J; Zhang X; Strout V
  • Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases.
    Mod Pathol Volume: 29 Page(s): 1575 - 1585
    12/01/2016 Authors: Reid MD; Balci S; Ohike N; Xue Y; Kim GE; Tajiri T; Memis B; Coban I; Dolgun A; Krasinskas AM
  • Radiation Therapy Compliance/Quality Assurance (QA) in 2 Phase 2 Trials of Cetuximab Plus Combined Modality Therapy (CMT) Including Chemotherapy and Radiation Therapy (RT) for Patients With Squamous Cell Carcinoma of the Anal Canal (SCCAC) (AMC045)
    Volume: 96 Page(s): S106 - S107
    10/01/2016 Authors: Garg MK; Zhao F; Lee J; Sparano J; Palefsky J; Henry D; Wachsman W; Rajdev L; Aboulafia D; Mitchell E
  • Long-term Survival in Stage IV Esophageal Adenocarcinoma with Chemoradiation and Serial Endoscopic Cryoablation
    Volume: 111 Page(s): S753 - S754
    10/01/2016 Authors: Spiritos Z; Mekaroonkamol P; Willingham F; El-Rayes B; Force S; Keilin S; Cai Q
  • Radiation Therapy Compliance/Quality Assurance (QA) in 2 Phase 2 Trials of Cetuximab Plus Combined Modality Therapy (CMT) Including Chemotherapy and Radiation Therapy (RT) for Patients With Squamous Cell Carcinoma of the Anal Canal (SCCAC) (AMC045)
    Volume: 96 Page(s): S106 - S107
    10/01/2016 Authors: Garg MK; Zhao F; Lee J; Sparano J; Palefsky J; Henry D; Wachsman W; Rajdev L; Aboulafia D; Mitchell E
  • Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases.
    Mod Pathol Volume: 29 Page(s): 1243 - 1253
    10/01/2016 Authors: Reid MD; Basturk O; Shaib WL; Xue Y; Balci S; Choi H-J; Akkas G; Memis B; Robinson BS; El-Rayes BF
  • A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
    Int J Radiat Oncol Biol Phys Volume: 96 Page(s): 296 - 303
    10/01/2016 Authors: Shaib WL; Hawk N; Cassidy RJ; Chen Z; Zhang C; Brutcher E; Kooby D; Maithel SK; Sarmiento JM; Landry J
  • Prolonged survival in hepatocarcinoma patients with increased regucalcin gene expression: HepG2 cell proliferation is suppressed by overexpression of regucalcin in vitro.
    Int J Oncol Volume: 49 Page(s): 1686 - 1694
    10/01/2016 Authors: Yamaguchi M; Osuka S; Weitzmann MN; El-Rayes BF; Shoji M; Murata T
  • Radiation Therapy Compliance/Quality Assurance (QA) in 2 Phase 2 Trials of Cetuximab Plus Combined Modality Therapy (CMT) Including Chemotherapy and Radiation Therapy (RT) for Patients With Squamous Cell Carcinoma of the Anal Canal (SCCAC) (AMC045).
    Int J Radiat Oncol Biol Phys Volume: 96 Page(s): S106 - S107
    10/01/2016 Authors: Garg MK; Zhao F; Lee J; Sparano J; Palefsky J; Henry D; Wachsman W; Rajdev L; Aboulafia D; Mitchell E
  • Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape.
    J Gastrointest Oncol Volume: 7 Page(s): 673 - 674
    10/01/2016 Authors: Bekaii-Saab T; El-Rayes B
  • Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial.
    J Surg Oncol Volume: 114 Page(s): 336 - 341
    09/01/2016 Authors: Postlewait LM; Ethun CG; Kooby DA; Sarmiento JM; Chen Z; Staley CA; Brutcher E; Adsay V; El-Rayes B; Maithel SK
  • Concurrent inhibition of NF-kappa B, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer (Retraction of vol 110, pg 171, 2010)
    JOURNAL OF CELLULAR BIOCHEMISTRY Volume: 117 Page(s): 1961 - 1961
    08/01/2016 Authors: Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
  • Treatment allocation in patients with early-stage esophageal adenocarcinoma: Prevalence and predictors of lymph node involvement.
    Cancer Volume: 122 Page(s): 2150 - 2157
    07/15/2016 Authors: Gamboa AM; Kim S; Force SD; Staley CA; Woods KE; Kooby DA; Maithel SK; Luke JA; Shaffer KM; Dacha S
  • Tolfenamic acid and curcumin treatment induces pancreatic cancer cell growth inhibition via suppressing Sp1 expression, NF-kB translocation to nucleus
    Volume: 76
    07/01/2016 Authors: Basha RM; Connelly SF; Purnachandra G; Sankpal UT; Patel H; Vishwanatha JK; Shelake S; Tabor-Simeckal L; Shoji M; Simecka JSW
  • Combination of HSP90 and proteasome inhibitor is effective in pancreatic cancer
    Volume: 76
    07/01/2016 Authors: Nagaraju GP; Rajitha B; Benton L; El-Rayes BF
  • Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System(pT1: 2, pT2: >2-4, pT3: >4 cm) is More Valid and Clinically Relevant.
    Ann Surg Oncol Volume: 23 Page(s): 2010 - 2018
    06/01/2016 Authors: Saka B; Balci S; Basturk O; Bagci P; Postlewait LM; Maithel S; Knight J; El-Rayes B; Kooby D; Sarmiento J
  • Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.
    Mol Ther Volume: 24 Page(s): 1150 - 1158
    06/01/2016 Authors: Noonan AM; Farren MR; Geyer SM; Huang Y; Tahiri S; Ahn D; Mikhail S; Ciombor KK; Pant S; Aparo S
  • FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
    Lancet Oncol Volume: 17 Page(s): 801 - 810
    06/01/2016 Authors: Suker M; Beumer BR; Sadot E; Marthey L; Faris JE; Mellon EA; El-Rayes BF; Wang-Gillam A; Lacy J; Hosein PJ
  • ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA)
    Volume: 27 Page(s): 109 - 109
    06/01/2016 Authors: Mazzaferro V; Shaib W; Rimassa L; Harris W; Personeni N; El-Rayes B; Tolcher A; Hall T; Wang Y; Schwartz B
  • Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI plus /-bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).
    Volume: 34
    05/20/2016 Authors: O'Neil BH; Hubbard JM; Starodub A; Jonker DJ; Edenfield WJ; El-Rayes BF; Halfdanarson TR; Ramanathan RK; Pitot HC; Britten CD
  • Uridine triacetate as a lifesaving antidote for overdoses and severe early-onset 5-fluorouracil and capecitabine toxicities.
    Volume: 34
    05/20/2016 Authors: Ma WW; Saif WM; Cartwright TH; Fakih M; El-Rayes BF; King T; Vanas J; von Borstel R; Bamat MK; Posey J
  • Uridine triacetate for early onset, severe life-threatening toxicities of 5-fluorouracil and capecitabine.
    Volume: 34
    05/20/2016 Authors: Cartwright TH; Ma WW; Fakih M; El-Rayes BF; Posey J; King T; Vanas J; von Borstel R; Bamat MK
  • Uridine triacetate as a life-saving antidote to capecitabine toxicity.
    Volume: 34
    05/20/2016 Authors: Ma WW; Cartwright TH; El-Rayes BF; Posey J; Fakih M; King T; von Borstel R; Bamat MK
  • Comparative features and overall survival in adenosquamous carcinoma, a rare tumor of the esophagus.
    Volume: 34
    05/20/2016 Authors: Evans M; Liu Y; Chen C; Gillespie TW; Steuer CE; Owonikoko TK; Ramalingam SS; Beitler JJ; El-Rayes BF; Fernandez F
  • Effect of definitive concurrent therapy with or without surgery on resectable esophageal cancer survival: An analysis of the National Cancer Data Base
    Volume: 34
    05/20/2016 Authors: Naik K; Liu Y; Goodman M; Gillespie TW; El-Rayes BF; Pickens A; Force S; Steuer CE; Owonikoko TK; Ramalingam SS
  • Prolonged survival in pancreatic cancer patients with increased regucalcin gene expression: Overexpression of regucalcin suppresses the proliferation in human pancreatic cancer MIA PaCa-2 cells in vitro.
    Int J Oncol Volume: 48 Page(s): 1955 - 1964
    05/01/2016 Authors: Yamaguchi M; Osuka S; Weitzmann MN; El-Rayes BF; Shoji M; Murata T
  • Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF-kB translocation to nucleus and cell cycle phase distribution.
    J Nutr Biochem Volume: 31 Page(s): 77 - 87
    05/01/2016 Authors: Basha R; Connelly SF; Sankpal UT; Nagaraju GP; Patel H; Vishwanatha JK; Shelake S; Tabor-Simecka L; Shoji M; Simecka JW
  • Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer.
    Med Oncol Volume: 33 Page(s): 48
    05/01/2016 Authors: Goldstein DA; Krishna K; Flowers CR; El-Rayes BF; Bekaii-Saab T; Noonan AM
  • Inhibition of NF-B translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer.
    Cancer Lett Volume: 373 Page(s): 227 - 233
    04/10/2016 Authors: Rajitha B; Belalcazar A; Nagaraju GP; Shaib WL; Snyder JP; Shoji M; Pattnaik S; Alam A; El-Rayes BF
  • Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome.
    Cancer Res Treat Volume: 48 Page(s): 596 - 604
    04/01/2016 Authors: Shaib W; Krishna K; Kim S; Goodman M; Rock J; Chen Z; Brutcher E; Staley CI; Maithel SK; Abdel-Missih S
  • Aquaporins: Their role in gastrointestinal malignancies.
    Cancer Lett Volume: 373 Page(s): 12 - 18
    04/01/2016 Authors: Nagaraju GP; Basha R; Rajitha B; Alese OB; Alam A; Pattnaik S; El-Rayes B
  • Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.
    J Mol Diagn Volume: 18 Page(s): 299 - 315
    03/01/2016 Authors: Fisher KE; Zhang L; Wang J; Smith GH; Newman S; Schneider TM; Pillai RN; Kudchadkar RR; Owonikoko TK; Ramalingam SS
  • Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic tumors of pancreatobiliary origin.
    Volume: 34
    02/01/2016 Authors: Kim HS; Camacho JC; El-Rayes BF
  • A molecular biomarker targeted approach to adjuvant therapy for resected pancreatic adenocarcinoma: Results of a phase II prospective trial.
    Volume: 34
    02/01/2016 Authors: Postlewait LM; Ethun CG; Kooby DA; Sarmiento J; Staley CA; Brutcher E; Adsay V; El-Rayes BF; Maithel SK
  • A phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Volume: 34
    02/01/2016 Authors: Shahda S; El-Rayes BF; O'Neil BH; Starodub A; Hanna WT; Borodyansky L; Oh C; Li C; Bekaii-Saab TS
  • Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
    Oncologist Volume: 21 Page(s): 178 - 187
    02/01/2016 Authors: Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
  • A Molecular Biomarker Targeted Approach to Adjuvant Therapy for Resected Pancreatic Adenocarcinoma: Results of a Phase II Prospective Trial
    Volume: 23 Page(s): S24 - S24
    02/01/2016 Authors: Postlewait LM; Ethun CG; Kooby DA; Sarmiento JM; Staley CA; Brutcher E; Adsay V; El-Rayes B; Maithel SK
  • Adenocarcinoma Ex-Goblet Cell Carcinoid (XGC) Is a Morphologically Distinct "Appendiceal-Type Crypt Cell" Adenocarcinoma with Highly Aggressive Behavior and Frequent Association with Peritoneal/Intra-Abdominal Dissemination: An Analysis of 77 Cases
    Volume: 96 Page(s): 194A - 194A
    02/01/2016 Authors: Reid M; Basturk O; Shaib W; Balci S; Choi H; Akkas G; Robinson B; Memis B; El-Rayes B; Staley C
  • Significant Prognostic Factors in Invasive Ampullary Adenocarcinoma (AC): Clinicopathologic Analysis of 367 Cases
    Volume: 29 Page(s): 194A - 194A
    02/01/2016 Authors: Reid M; Balci S; Xue Y; Ohike N; Tajiri T; Basturk O; Muraki T; Kim GE; Krasinskas AM; Quigley B
  • Adenocarcinoma Ex-Goblet Cell Carcinoid (XGC) Is a Morphologically Distinct "Appendiceal-Type Crypt Cell" Adenocarcinoma with Highly Aggressive Behavior and Frequent Association with Peritoneal/Intra-Abdominal Dissemination: An Analysis of 77 Cases
    Volume: 29 Page(s): 194A - 194A
    02/01/2016 Authors: Reid M; Basturk O; Shaib W; Balci S; Choi H; Akkas G; Robinson B; Memis B; El-Rayes B; Staley C
  • Clinical trial experience with uridine triacetate for 5-fluorouracil toxicity.
    Volume: 34
    02/01/2016 Authors: Ma WW; Saif WM; El-Rayes BF; Fakih M; Cartwright TH; Posey J; von Borstel R; Bamat MK
  • Significant Prognostic Factors in Invasive Ampullary Adenocarcinoma (AC): Clinicopathologic Analysis of 367 Cases
    Volume: 96 Page(s): 194A - 194A
    02/01/2016 Authors: Reid M; Balci S; Xue Y; Ohike N; Tajiri T; Basturk O; Muraki T; Kim GE; Krasinskas AM; Quigley B
  • Combination of tolfenamic acid and curcumin induces colon cancer cell growth inhibition through modulating specific transcription factors and reactive oxygen species.
    Oncotarget Volume: 7 Page(s): 3186 - 3200
    01/19/2016 Authors: Sankpal UT; Nagaraju GP; Gottipolu SR; Hurtado M; Jordan CG; Simecka JW; Shoji M; El-Rayes B; Basha R
  • Adjuvant therapy for pancreas cancer in an era of value based cancer care.
    Cancer Treat Rev Volume: 42 Page(s): 10 - 17
    01/01/2016 Authors: Ahn DH; Williams TM; Goldstein DA; El-Rayes B; Bekaii-Saab T
  • MicroRNAs as biomarkers and prospective therapeutic targets in colon and pancreatic cancers.
    Tumour Biol Volume: 37 Page(s): 97 - 104
    01/01/2016 Authors: Nagaraju GP; Madanraj AS; Aliya S; Rajitha B; Alese OB; Kariali E; Alam A; El-Rayes BF
  • Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Eur J Cancer Volume: 52 Page(s): 109 - 119
    01/01/2016 Authors: Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
  • Broad targeting of angiogenesis for cancer prevention and therapy.
    Semin Cancer Biol Volume: 35 Suppl Page(s): S224 - S243
    12/01/2015 Authors: Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D
  • Substaging Nodal Status in Ampullary Carcinomas has Significant Prognostic Value: Proposed Revised Staging Based on an Analysis of 313 Well-Characterized Cases.
    Volume: 22 Page(s): 4392 - 4401
    12/01/2015 Authors: Balci S; Basturk O; Saka B; Bagci P; Postlewait LM; Tajiri T; Jang K-T; Ohike N; Kim GE; Krasinskas A
  • Clinicopathologic Features and Outcome of Young Adults With Stage IV Colorectal Cancer.
    Am J Clin Oncol Volume: 38 Page(s): 543 - 549
    12/01/2015 Authors: Hawk NN; Long T-E; Imam MH; Mathew BM; Kim S; Chen Z; Goodman M; Sullivan P; Brutcher E; Kauh J
  • Analysis of liver-directed therapies in U.S. cancer patients.
    Curr Oncol Volume: 22 Page(s): e457 - e461
    12/01/2015 Authors: Alese OB; Kim S; Chen Z; Ramalingam SS; Owonikoko TK; El-Rayes BF
  • Designing a broad-spectrum integrative approach for cancer prevention and treatment.
    Semin Cancer Biol Volume: 35 Suppl Page(s): S276 - S304
    12/01/2015 Authors: Block KI; Gyllenhaal C; Lowe L; Amedei A; Amin ARMR; Amin A; Aquilano K; Arbiser J; Arreola A; Arzumanyan A
  • Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TNM Staging.
    Ann Surg Oncol Volume: 22 Suppl 3 Page(s): S1187 - S1195
    12/01/2015 Authors: Basturk O; Saka B; Balci S; Postlewait LM; Knight J; Goodman M; Kooby D; Sarmiento JM; El-Rayes B; Choi H
  • The flavonoid p-hydroxycinnamic acid exhibits anticancer effects in human pancreatic cancer MIA PaCa-2 cells in vitro: Comparison with gemcitabine.
    Oncol Rep Volume: 34 Page(s): 3304 - 3310
    12/01/2015 Authors: Yamaguchi M; Murata T; El-Rayes BF; Shoji M
  • Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.
    Volume: 33 Page(s): 3727 - 3732
    11/10/2015 Authors: Goldstein DA; Ahmad BB; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
  • Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al.
    J Clin Oncol Volume: 33 Page(s): 3842 - 3843
    11/10/2015 Authors: Goldstein DA; El-Rayes BF; Chen Q; Flowers CR
  • Biomarkers for personalized medicine in GI cancers.
    Mol Aspects Med Volume: 45 Page(s): 14 - 27
    11/01/2015 Authors: Zhang SY; Zhang SQ; Nagaraju GP; El-Rayes BF
  • Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer.
    Mol Carcinog Volume: 54 Page(s): 1147 - 1158
    10/01/2015 Authors: Nagaraju GP; Long T-E; Park W; Landry JC; Taliaferro-Smith L; Farris AB; Diaz R; El-Rayes BF
  • Hypoxia inducible factor-1: Its role in colorectal carcinogenesis and metastasis.
    Cancer Lett Volume: 366 Page(s): 11 - 18
    09/28/2015 Authors: Nagaraju GP; Bramhachari PV; Raghu G; El-Rayes BF
  • Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?
    Oncologist Volume: 20 Page(s): 981 - 982
    09/01/2015 Authors: Goldstein DA; El-Rayes BF
  • Inhibition of NF-kappa B translocation induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer
    Volume: 75
    08/01/2015 Authors: Nagaraju GP; Olatunji A; Gupta S; Shoji M; El-Rayes BF
  • A phase I pharmacokinetic and pharmacodynamic evaluation of the combination of everolimus and buparlisib for concurrent mTOR and PI3K pathway blockade in patients with advanced solid tumors
    Volume: 75
    08/01/2015 Authors: Owonikoko TK; Harvey RD; Lewis C; Chen Z; Kauh JS; Renfroe M; Deovic R; Sica GL; Carthon BC; Harris WB
  • Targeting NF-kappa B by the curcumin and its analogs EF-31 and UBS-109 decreases growth and angiogenesis of colon cancer
    Volume: 75
    08/01/2015 Authors: Nagaraju GP; Shoji M; El Rayes B
  • PIK3CA/BRAF mutations negatively affect outcome of patients with KRAS wild-type metastatic colorectal cancer treated with front line anti-EGFR monoclonal antibodies: Meta-analysis results
    Volume: 75
    08/01/2015 Authors: Mohamed A; Schrapp K; Attumi T; Saba NF; El-Rayes BF
  • Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients With Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis From Three Tertiary Care Centers.
    Oncologist Volume: 20 Page(s): 907 - 914
    08/01/2015 Authors: Shaib WL; Martin LK; Choi M; Chen Z; Krishna K; Kim S; Brutcher E; Staley C; Maithel SK; Philip P
  • Combination of anti-cancer small molecule tolfenamic acid and curcumin effectively inhibits colon cancer cell growth
    Volume: 75
    08/01/2015 Authors: Sankpal UT; Nagaraju GP; Hurtado M; Gottipolu SR; El-Rayes B; Shoji M; Jordan CG; Basha R
  • Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.
    Volume: 22 Page(s): 2295 - 2301
    07/01/2015 Authors: Squires MH; Volkan Adsay N; Schuster DM; Russell MC; Cardona K; Delman KA; Winer JH; Altinel D; Sarmiento JM; El-Rayes B
  • Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
    Cancer Volume: 121 Page(s): 2164 - 2174
    07/01/2015 Authors: Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
  • Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    J Gastroenterol Hepatol Volume: 30 Page(s): 1167 - 1174
    07/01/2015 Authors: Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
  • Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States.
    World J Oncol Volume: 6 Page(s): 349 - 354
    06/01/2015 Authors: Alese OB; Kim S; Chen Z; Shaib W; Staley CA; Ramalingam SS; Owonikoko TK; El-Rayes BF
  • Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
    J Surg Oncol Volume: 111 Page(s): 1028 - 1034
    06/01/2015 Authors: Nanda RH; El-Rayes B; Maithel SK; Landry J
  • Radiotherapy patterns of care in gastric adenocarcinoma: a single institution experience.
    J Gastrointest Oncol Volume: 6 Page(s): 247 - 253
    06/01/2015 Authors: Cheng J; Squires MH; Mikell JL; Fisher SB; Staley CA; Kooby DA; El-Rayes BF; Curran WJ; Hall WA; Colbert LE
  • Management patterns and predictors of mortality among US patients with cancer hospitalized for malignant bowel obstruction.
    Cancer Volume: 121 Page(s): 1772 - 1778
    06/01/2015 Authors: Alese OB; Kim S; Chen Z; Owonikoko TK; El-Rayes BF
  • Phase I study of ganetespib (G), capecitabine (C), and radiation (RT) in rectal cancer
    Volume: 33
    05/20/2015 Authors: El-Rayes BF; Staley CA; Diaz R; Sullivan PS; Shaib WL; Landry JC
  • Pattern of liver-directed therapies and outcomes in cancer patients hospitalized in the United States
    Volume: 33
    05/20/2015 Authors: Alese OB; Kim S; Chen Z; Owonikoko TK; El-Rayes BF
  • Management and outcomes of hospitalized patients with primary neuroendocrine tumor (NET) and non-NET appendiceal cancers in the United States.
    Volume: 33
    05/20/2015 Authors: Alese OB; Kim S; Chen Z; Shaib WL; Owonikoko TK; El-Rayes BF
  • Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer
    Volume: 33
    05/20/2015 Authors: Goldstein DA; Ahmad BB; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers C
  • Borderline resectable (BRPC) and locally advanced unresectable (LAPC) pancreas cancer treatment: A single Institution experience.
    Volume: 33
    05/20/2015 Authors: Shaib WL; Qu J; Zhang C; Ip A; Chen Z; El-Rayes BF; Alese O
  • Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody.
    J Drug Target Volume: 23 Page(s): 257 - 265
    04/01/2015 Authors: Zhu S; Kisiel W; Lu YJ; Petersen LC; Ndungu JM; Moore TW; Parker ET; Sun A; Sarkaria JN; Snyder JP
  • First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
    J Clin Oncol Volume: 33 Page(s): 1112 - 1118
    04/01/2015 Authors: Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
  • Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines.
    Cancer Med Volume: 4 Page(s): 392 - 403
    03/01/2015 Authors: Goecks J; El-Rayes BF; Maithel SK; Khoury HJ; Taylor J; Rossi MR
  • High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected pancreatic adenocarcinoma.
    Int J Radiat Oncol Biol Phys Volume: 91 Page(s): 631 - 639
    03/01/2015 Authors: Colbert LE; Fisher SB; Balci S; Saka B; Chen Z; Kim S; El-Rayes BF; Adsay NV; Maithel SK; Landry JC
  • Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.
    Ther Adv Med Oncol Volume: 7 Page(s): 56 - 62
    03/01/2015 Authors: Alese OB; El-Rayes BF; Sica G; Zhang G; Alexis D; La Rosa FG; Varella-Garcia M; Chen Z; Rossi MR; Adsay NV
  • Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer.
    Cancer Lett Volume: 357 Page(s): 557 - 565
    02/28/2015 Authors: Nagaraju GP; Zhu S; Ko JE; Ashritha N; Kandimalla R; Snyder JP; Shoji M; El-Rayes BF
  • Comprehensive Genomic Profiling (CGP) of 122 Appendiceal Tumors Identifies Genomic Alterations (GA) Associated With Neuroendocrine and Signet Ring Differentiation
    Volume: 95 Page(s): 158A - 159A
    02/01/2015 Authors: Elvin J; Goldstein D; Wang K; Chalmers Z; Ali S; Chmielecki J; Stephens P; Lipson D; Yelensky R; Miller V
  • Comprehensive Genomic Profiling (CGP) of 122 Appendiceal Tumors Identifies Genomic Alterations (GA) Associated With Neuroendocrine and Signet Ring Differentiation
    Volume: 28 Page(s): 158A - 159A
    02/01/2015 Authors: Elvin J; Goldstein D; Wang K; Chalmers Z; Ali S; Chmielecki J; Stephens P; Lipson D; Yelensky R; Miller V
  • The anatomic location of pancreatic cancer as a prognostic factor for inpatient complications.
    Volume: 33
    01/20/2015 Authors: Zhang SY; Zhang SQ; Jiang JJ; El-Rayes BF
  • Prognostic value of gender in hospitalized pancreatic patients.
    Volume: 33
    01/20/2015 Authors: Zhang SY; Zhang SQ; Jiang JJ; El-Rayes BF
  • Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer (mPC).
    Volume: 33
    01/20/2015 Authors: Goldstein DA; Krishna K; Flowers C; El-Rayes BF; Bekaii-Saab TS; Noonan AM
  • Comprehensive genomic profiling of cancer of the appendix to reveal new routes to targeted therapies.
    Volume: 33
    01/20/2015 Authors: Goldstein DA; Elvin JA; Wang K; Shaib WL; Rossi MR; Stephens PJ; Ross JS; El-Rayes BF
  • Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    AJR Am J Roentgenol Volume: 203 Page(s): W706 - W714
    12/01/2014 Authors: Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
  • Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer.
    Clin Colorectal Cancer Volume: 13 Page(s): 219 - 225
    12/01/2014 Authors: Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Harvey RD; El-Rayes BF; Flowers CR
  • Hepatoid adenocarcinoma of the lung: a case report and review of the literature.
    J Gastrointest Cancer Volume: 45 Suppl 1 Page(s): 99 - 102
    12/01/2014 Authors: Shaib W; Sharma R; Mosunjac M; Farris AB; El Rayes B
  • Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer.
    Oncogene Volume: 33 Page(s): 5450 - 5456
    11/20/2014 Authors: Hall WA; Petrova AV; Colbert LE; Hardy CW; Fisher SB; Saka B; Shelton JW; Warren MD; Pantazides BG; Gandhi K
  • Ethnic, gender, and age disparities and outcome of phase I clinical trials of biologically targeted anticancer agents
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION Volume: 23
    11/01/2014 Authors: Owonikoko TK; Lewis C; Busari AK; Kim S; Chen Z; Lawson DH; Carthon BC; El-Rayes BF; Khuri FR; Kauh J
  • HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy.
    Oncotarget Volume: 5 Page(s): 9980 - 9991
    10/30/2014 Authors: Nagaraju GP; Alese OB; Landry J; Diaz R; El-Rayes BF
  • Combination of anti-cancer small molecule tolfenamic acid and curcumin or curcumin analog EF31 effectively inhibits pancreatic cancer cell growth
    Volume: 74
    10/01/2014 Authors: Basha R; Connelly SF; Nagaraju GP; Sankpal UT; Shoji M; Kayaleh O; El-Rayes B
  • Functional inhibition of HSP90 induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer
    Volume: 74
    10/01/2014 Authors: Nagaraju GP; Willingham FF; Woods KE; Sullivan P; Landry JC; Diaz R; El-Rayes BF
  • HSP90 as a therapeutic target in colorectal cancer
    Volume: 74
    10/01/2014 Authors: Nagaraju GP; Willingham FF; Woods KE; Sullivan P; Landry JC; Diaz R; El-Rayes BF
  • Nuclear Hypoxia-Inducible Factor 1 Alpha is a Predictor of Distant Failure in Patients With Resected Pancreatic Adenocarcinoma
    Volume: 90 Page(s): S49 - S49
    09/01/2014 Authors: Colbert L; Fisher SB; Balci S; Chen Z; Kim S; Adsay NV; Maithel SK; El-Rayes BF; Landry JC; Curran WJ
  • Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients.
    Ann Surg Volume: 260 Page(s): 494 - 501
    09/01/2014 Authors: Kooby DA; Lad NL; Squires MH; Maithel SK; Sarmiento JM; Staley CA; Adsay NV; El-Rayes BF; Weber SM; Winslow ER
  • Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer.
    Invest New Drugs Volume: 32 Page(s): 682 - 690
    08/01/2014 Authors: Bendell JC; Lenz H-J; Ryan T; El-Rayes BF; Marshall JL; Modiano MR; Hart LL; Kingsley CD; George TJ; Nakashima D
  • Locoregional therapies for metastatic colorectal carcinoma to the liver--an evidence-based review.
    J Surg Oncol Volume: 110 Page(s): 182 - 196
    08/01/2014 Authors: Xing M; Kooby DA; El-Rayes BF; Kokabi N; Camacho JC; Kim HS
  • Targeted therapies in metastatic esophageal cancer: advances over the past decade.
    Crit Rev Oncol Hematol Volume: 91 Page(s): 186 - 196
    08/01/2014 Authors: Mohamed A; El-Rayes B; Khuri FR; Saba NF
  • Cost-effectiveness analysis of pharmacokinetic-guided (PK) 5-fluorouracil (5FU) when combined with leucovorin and oxaliplatin (FOLFOX) chemotherapy for metastatic colorectal cancer (mCRC)
    Volume: 32
    05/20/2014 Authors: Goldstein DA; Chen Q; Howard DH; Lipscomb J; Ayer T; Harvey D; El-Rayes BF; Flowers C
  • Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC)
    Volume: 32
    05/20/2014 Authors: Goldstein DA; Chen Q; Howard DH; Lipscomb J; Ayer T; El-Rayes BF; Flowers C
  • Mortality from malignant bowel obstruction in hospitalized US cancer patients
    Volume: 32
    05/20/2014 Authors: Alese OB; Kim S; Chen Z; Owonikoko TK; El-Rayes BF
  • CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.
    Cancer Res Volume: 74 Page(s): 2677 - 2687
    05/15/2014 Authors: Colbert LE; Petrova AV; Fisher SB; Pantazides BG; Madden MZ; Hardy CW; Warren MD; Pan Y; Nagaraju GP; Liu EA
  • Trends in the Incidence of Esophageal Adenocarcinoma and Early Stage Esophageal Adenocarcinoma in the United States
    Volume: 146 Page(s): S566 - S567
    05/01/2014 Authors: Gamboa AM; Kim S; Chen Z; Woods KE; Keilin S; Cai Q; Saba N; El-Rayes B; Willingham FF
  • Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis.
    Carcinogenesis Volume: 35 Page(s): 967 - 973
    05/01/2014 Authors: Nagaraju GP; Dontula R; El-Rayes BF; Lakka SS
  • Treatment utilization and surgical outcome of ampullary and duodenal adenocarcinoma.
    J Surg Oncol Volume: 109 Page(s): 556 - 560
    05/01/2014 Authors: Shaib WL; Sharma R; Brutcher E; Kim S; Maithel SK; Chen Z; Kooby DA; Kauh J; Landry J; El-Rayes BF
  • Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma.
    Am J Clin Oncol Volume: 37 Page(s): 194 - 200
    04/01/2014 Authors: Zafar SF; El-Rayes BF
  • Imaging and curcumin delivery in pancreatic cancer cell lines using PEGylated -Gd2(MoO4)3 mesoporous particles.
    Dalton Trans Volume: 43 Page(s): 3330 - 3338
    02/28/2014 Authors: Seeta Rama Raju G; Pavitra E; Nagaraju GP; Ramesh K; El-Rayes BF; Yu JS
  • Clinicopathologic Associations of Mismatch Repair Protein Expressions in Ampullary Carcinomas
    Volume: 27 Page(s): 164A - 164A
    02/01/2014 Authors: Balci S; Saka B; Krasinskas A; Kim G; Dursun N; Shaib W; El-Rayes B; Quigley B; Reid M; Farris AB
  • Clinicopathologic Associations of Mismatch Repair Protein Expressions in Ampullary Carcinomas
    Volume: 94 Page(s): 164A - 164A
    02/01/2014 Authors: Balci S; Saka B; Krasinskas A; Kim G; Dursun N; Shaib W; El-Rayes B; Quigley B; Reid M; Farris AB
  • Proposal for a Revised N-Stage for Pancreatic Ductal Adenocarcinoma as N1 (< 3) and N2 (>= 3) with Strong Prognostic Correlation
    Volume: 27 Page(s): 448A - 448A
    02/01/2014 Authors: Choi H; Saka B; Balci S; Basturk O; Maithel S; Kooby D; Sarmiento J; El-Rayes B; Knight J; Goodman M
  • HER2 in resected gastric cancer: Is there prognostic value?
    J Surg Oncol Volume: 109 Page(s): 61 - 66
    02/01/2014 Authors: Fisher SB; Fisher KE; Squires MH; Patel SH; Kooby DA; El-Rayes BF; Cardona K; Russell MC; Staley CA; Farris AB
  • Proposal for a New and Prognostically Valuable Tumor Size Based T-Stage for Pancreatic Adenocarcinoma
    Volume: 94 Page(s): 453A - 453A
    02/01/2014 Authors: Saka B; Balci S; Bagci P; Maithel S; Kooby D; Sarmiento J; Staley C; El-Rayes B; Choi H; Knight J
  • Abundance of IGG4-Positive Plasma Cells in Post-Neoadjuvant Ulcers of Gastroesophageal Carcinomas
    Volume: 94 Page(s): 174A - 174A
    02/01/2014 Authors: Genco I; Saka B; Balci S; Bradley K; Farris AB; Khosroshahi A; El-Rayes B; Krasinskas A; Staley C; Kooby D
  • Abundance of IGG4-Positive Plasma Cells in Post-Neoadjuvant Ulcers of Gastroesophageal Carcinomas
    Volume: 27 Page(s): 174A - 174A
    02/01/2014 Authors: Genco I; Saka B; Balci S; Bradley K; Farris AB; Khosroshahi A; El-Rayes B; Krasinskas A; Staley C; Kooby D
  • Will the pT1 and pT2 Pancreas Cancer Please Stand Up? "Peripancreatic Soft Tissue" Is Involved in Most Pancreatic Ductal Adenocarcinomas (PDAC), Negating Its Value as a Staging Parameter and Necessitating a New Staging Scheme
    Volume: 27 Page(s): 454A - 454A
    02/01/2014 Authors: Saka B; Oliva I; Bandyopadhyay S; Basturk O; Balci S; Maithel S; Kooby D; Sarmiento J; Staley C; El-Rayes B
  • Sub-Staging of Nodal Status in Ampullary Carcinomas as N1 (< 3) and N2(>= 3) Has Significant Prognostic Value: Proposal for Revised Staging Based on an Analysis of 313 Cases
    Volume: 94 Page(s): 164A - 164A
    02/01/2014 Authors: Bagci P; Balci S; Saka B; Hong S-M; Jang K-T; Ohike N; Kim G; Krasinskas A; Basturk O; Sarmiento J
  • Proposal for a Revised N-Stage for Pancreatic Ductal Adenocarcinoma as Ni (< 3) and N2
    Volume: 94 Page(s): 448A - 448A
    02/01/2014 Authors: Choi H; Saka B; Balci S; Basturk O; Maithel S; Kooby D; Sarmiento J; El-Rayes B; Knight J; Goodman M
  • Will the pT1 and pT2 Pancreas Cancer Please Stand Up? "Peripancreatic Soft Tissue" Is Involved in Most Pancreatic Ductal Adenocarcinomas (PDAC), Negating Its Value as a Staging Parameter and Necessitating a New Staging Scheme
    Volume: 94 Page(s): 454A - 454A
    02/01/2014 Authors: Saka B; Oliva I; Bandyopadhyay S; Basturk O; Balci S; Maithel S; Kooby D; Sarmiento J; Staley C; El-Rayes B
  • Proposal for a New and Prognostically Valuable Tumor Size Based T-Stage for Pancreatic Adenocarcinoma
    Volume: 27 Page(s): 453A - 453A
    02/01/2014 Authors: Saka B; Balci S; Bagci P; Maithel S; Kooby D; Sarmiento J; Staley C; El-Rayes B; Choi H; Knight J
  • Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
    J Vasc Interv Radiol Volume: 25 Page(s): 256 - 265
    02/01/2014 Authors: Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
  • Association of radiation therapy with overall survival in patients undergoing surgery for T3N0M0 adenocarcinoma of the rectum.
    Volume: 32
    01/20/2014 Authors: Marcus DM; Nickleach D; El-Rayes BF; Landry JC
  • Open-label prospective study of safety and efficacy of glass-based Y-90 radioembolization for infiltrative HCC with PVT
    Volume: 32
    01/20/2014 Authors: Kokabi N; Camacho JC; Xing M; Kauh JS; El-Rayes BF; Kim HS
  • Survival trends in unresectable hepatocellular carcinoma and the effect of DEB-TACE: SEER versus tertiary cancer center
    Volume: 32
    01/20/2014 Authors: Xing M; Prajapati HJ; Kokabi N; Camacho JC; El-Rayes BF; Kim HS
  • Survival trends in chemorefractory unresectable intrahepatic cholangiocarcinoma (ICC) and the effect of yttrium-90 (Y90) radioembolization: SEER versus tertiary cancer center
    Volume: 32
    01/20/2014 Authors: Xing M; Prajapati HJ; Kokabi N; Camacho JC; El-Rayes BF; Kim HS
  • Tumor angiogenesis therapy using targeted delivery of Paclitaxel to the vasculature of breast cancer metastases.
    J Drug Deliv Volume: 2014 Page(s): 865732
    01/01/2014 Authors: Zhu S; Kisiel W; Lu YJ; Petersen LC; Ndungu JM; Moore TW; Parker ET; Sun A; Liotta DC; El-Rayes BF
  • Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer.
    Cancer Lett Volume: 341 Page(s): 195 - 203
    12/01/2013 Authors: Nagaraju GP; Zhu S; Wen J; Farris AB; Adsay VN; Diaz R; Snyder JP; Mamoru S; El-Rayes BF
  • Incidence and prognosis of gastroesophageal cancer in rural, urban, and metropolitan areas of the United States.
    Cancer Volume: 119 Page(s): 4020 - 4027
    11/15/2013 Authors: Wang Z; Goodman M; Saba N; El-Rayes BF
  • Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
    Pancreas Volume: 42 Page(s): 1311 - 1315
    11/01/2013 Authors: Mahaseth H; Brutcher E; Kauh J; Hawk N; Kim S; Chen Z; Kooby DA; Maithel SK; Landry J; El-Rayes BF
  • Geographic differences in approach to advanced gastric cancer: Is there a standard approach?
    Crit Rev Oncol Hematol Volume: 88 Page(s): 416 - 426
    11/01/2013 Authors: Kim R; Tan A; Choi M; El-Rayes BF
  • Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1 and STAT-3.
    Angiogenesis Volume: 16 Page(s): 903 - 917
    10/01/2013 Authors: Nagaraju GP; Park W; Wen J; Mahaseth H; Landry J; Farris AB; Willingham F; Sullivan PS; Proia DA; El-Hariry I
  • Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma.
    Cancer Volume: 119 Page(s): 3148 - 3155
    09/01/2013 Authors: Colbert LE; Fisher SB; Hardy CW; Hall WA; Saka B; Shelton JW; Petrova AV; Warren MD; Pantazides BG; Gandhi K
  • Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma.
    Cancer Volume: 119 Page(s): 3242 - 3250
    09/01/2013 Authors: Squires MH; Fisher SB; Fisher KE; Patel SH; Kooby DA; El-Rayes BF; Staley CA; Farris AB; Maithel SK
  • Clinico-pathological characteristics of younger, middle aged, and older patients with colon cancer
    Volume: 49 Page(s): S526 - S526
    09/01/2013 Authors: Salem M; Kaufman M; Stanski N; Dyson G; Krasnick B; Choi M; Hawk N; El-Rayes B; Philip P
  • Markers of resistance to anti-EGFR therapy in colorectal cancer.
    J Gastrointest Oncol Volume: 4 Page(s): 308 - 318
    09/01/2013 Authors: Shaib W; Mahajan R; El-Rayes B
  • Pleiotropic effects of genistein in metabolic, inflammatory, and malignant diseases.
    Nutr Rev Volume: 71 Page(s): 562 - 572
    08/01/2013 Authors: Nagaraju GP; Zafar SF; El-Rayes BF
  • 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness.
    J Comp Eff Res Volume: 2 Page(s): 435 - 444
    07/01/2013 Authors: Xing M; Kokabi N; Camacho JC; Kooby DA; El-Rayes BF; Kim HS
  • In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells.
    Int J Radiat Oncol Biol Phys Volume: 86 Page(s): 469 - 476
    07/01/2013 Authors: Shelton JW; Waxweiler TV; Landry J; Gao H; Xu Y; Wang L; El-Rayes B; Shu H-KG
  • Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma.
    J Gastrointest Cancer Volume: 44 Page(s): 143 - 151
    06/01/2013 Authors: Carr JS; Zafar SF; Saba N; Khuri FR; El-Rayes BF
  • Survival outcome of ampullary and duodenal adenocarcinomas.
    Volume: 31
    05/20/2013 Authors: Shaib WL; Sharma R; Kim S; Chen Z; Kauh JS; Kooby DA; Maithel SK; Landry JC; El-Rayes BF
  • A retrospective cohort study of inpatient chemotherapy utilization in hospitalized advanced lung cancer patients in the United States.
    Volume: 31
    05/20/2013 Authors: Kang H; Kim S; Chen Z; El-Rayes BF; Brandes JC; Saba NF; Khuri FR; Ramalingam SS; Owonikoko TK
  • Multiplatform assessment of anaplastic lymphoma kinase (ALK) gene rearrangement in signet ring cell carcinoma of the gastrointestinal tract
    Volume: 31
    05/20/2013 Authors: Alese OB; El-Rayes BF; Sica G; Zhang G; Rossi MR; Adsay V; Alexis D; La Rosa FG; Varella-Garcia M; Chen Z
  • Doxorubicin drug eluting beads transcatheter chemoembolization (DEB TACE) in patients with large hepatocellular carcinoma (HCC): Overall survival and a multivariate analysis (MVA) of prognostic factors.
    Volume: 31
    05/20/2013 Authors: Prajapati HJ; Spivey JR; El-Rayes BF; Kauh JS; Kim HS
  • Early therapy response assessment by apparent diffusion coefficient (ADC) quantification following glass-based yttrium-90 radioembolization for unresectable hepatocellular carcinoma (HCC).
    Volume: 31
    05/20/2013 Authors: Kokabi N; Camacho JC; El-Rayes BF; Kauh JS; Kim HS
  • Heat shock protein 90 functional inhibition regulates epithelial to mesenchymal transformation, invasion and migration via NF-kB and HIF-1 alpha signaling in colorectal cancer
    Volume: 73
    04/15/2013 Authors: Ganji P; Long T-E; Mummareddi PM; Park W; Willingham FF; Landry JC; Sullivan P; Taliaferro-Smith L; Diaz R; El-Rayes B
  • A pilot clinical trial of chromodomain-helicase-DNA-binding protein 7 (CHD7) expression as a prognostic and predictive biomarker in patients with early-stage pancreatic adenocarcinoma.
    Volume: 73
    04/15/2013 Authors: Colbert LE; Hall WA; Hardy CW; Fisher SB; Yu DS; Maithel SK; El-Rayes B; Saka B; Adsay NV; Petrova A
  • mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
    Ann Oncol Volume: 24 Page(s): 965 - 973
    04/01/2013 Authors: Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
  • Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline.
    J Clin Oncol Volume: 31 Page(s): 1357 - 1370
    04/01/2013 Authors: Schiffer CA; Mangu PB; Wade JC; Camp-Sorrell D; Cope DG; El-Rayes BF; Gorman M; Ligibel J; Mansfield P; Levine M
  • Antiangiogenic activity of the HSP90 inhibitor ganetespib in pancreatic cancer models
    Volume: 27
    04/01/2013 Authors: Ganji PN; Diaz R; El-Rayes B
  • Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study.
    Cardiovasc Intervent Radiol Volume: 36 Page(s): 440 - 448
    04/01/2013 Authors: Rafi S; Piduru SM; El-Rayes B; Kauh JS; Kooby DA; Sarmiento JM; Kim HS
  • Anti-angiogenic effects of curcumin and its novel analogs EF-31 and UBS-109 in colorectal cancer
    Volume: 27
    04/01/2013 Authors: Ganji PN; Zhu S; Ko JE; Shoji M; El-Rayes B
  • A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
    Br J Cancer Volume: 108 Page(s): 762 - 765
    03/05/2013 Authors: Harvey RD; Owonikoko TK; Lewis CM; Akintayo A; Chen Z; Tighiouart M; Ramalingam SS; Fanucchi MP; Nadella P; Rogatko A
  • Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    J Vasc Interv Radiol Volume: 24 Page(s): 307 - 315
    03/01/2013 Authors: Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
  • Detailed Evaluation of the Lymph Nodes in N0 Cases with Additional Levels Ought To Be Considered for the Accurate Staging of Proximal Biliary Tract Cancers
    Volume: 26 Page(s): 397A - 398A
    02/01/2013 Authors: Bagci P; Maithel S; Fisher S; Saka B; Ocuin L; Patel S; Kooby D; Staley C; Sarmiento J; El-Rayes B
  • Neuroendocrine tumors (NET) of the gastrointestinal tract: Patterns of management and experience at Winship Cancer Institute of Emory University
    Volume: 31
    02/01/2013 Authors: Zafar SF; Patil DH; Kauh JS; Adsay V; Brutcher E; Maithel SK; Wang Z; Chen Z; El-Rayes BF
  • Clinicopathologic Comparison of Ampullary Versus Pancreatic Carcinoma: Preinvasive Component, Size of Invasion, Stage, Resectability and Histologic Phenotype Are the Factors for the Significantly Favorable Outcome of Ampullary Carcinoma
    Volume: 26 Page(s): 429A - 429A
    02/01/2013 Authors: Saka B; Tajiri T; Ohike N; Bagci P; Krasinskas A; Kim GE; Maithel SK; Sarmiento J; Kooby D; Ozdemir D
  • Clinicopathologic Comparison of Ampullary Versus Pancreatic Carcinoma: Preinvasive Component, Size of Invasion, Stage, Resectability and Histologic Phenotype Are the Factors for the Significantly Favorable Outcome of Ampullary Carcinoma
    Volume: 93 Page(s): 429A - 429A
    02/01/2013 Authors: Saka B; Tajiri T; Ohike N; Bagci P; Krasinskas A; Kim GE; Maithel SK; Sarmiento J; Kooby D; Ozdemir D
  • Differential Expression and Prognostic Value of ERCC1 and Thymidylate Synthase in Resected Gastric Adenocarcinoma
    Volume: 20 Page(s): S138 - S138
    02/01/2013 Authors: Squires MH; Fisher SB; Fisher KE; Patel SH; Kooby D; Staley CA; Farris AB; Maithel SK
  • Detailed Evaluation of the Lymph Nodes in N0 Cases with Additional Levels Ought To Be Considered for the Accurate Staging of Proximal Biliary Tract Cancers
    Volume: 93 Page(s): 397A - 398A
    02/01/2013 Authors: Bagci P; Maithel S; Fisher S; Saka B; Ocuin L; Patel S; Kooby D; Staley C; Sarmiento J; El-Rayes B
  • Neoplasms and Pseudotumors Associated with Low (Intrapancreatic) Union of Cystic Duct into Common Bile Duct: A Clinicopathologic Analysis of 15 Cases of a Hitherto Unrecognized Phenomenon
    Volume: 93 Page(s): 424A - 424A
    02/01/2013 Authors: Gonzalez RS; Saka B; Bagci P; Erbarut I; Maithel SK; Kooby D; Staley C; El-Rayes B; Sarmiento J; Everett R
  • Neoplasms and Pseudotumors Associated with Low (Intrapancreatic) Union of Cystic Duct into Common Bile Duct: A Clinicopathologic Analysis of 15 Cases of a Hitherto Unrecognized Phenomenon
    Volume: 26 Page(s): 424A - 424A
    02/01/2013 Authors: Gonzalez RS; Saka B; Bagci P; Erbaraut I; Maithel SK; Kooby D; Staley C; El-Rayes B; Sarmiento J; Everett R
  • An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.
    Cancer Volume: 119 Page(s): 445 - 453
    01/15/2013 Authors: Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Maithel SK
  • Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
    Cancer Volume: 119 Page(s): 285 - 292
    01/15/2013 Authors: Bauer TM; El-Rayes BF; Li X; Hammad N; Philip PA; Shields AF; Zalupski MM; Bekaii-Saab T
  • Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
    Cancer Volume: 119 Page(s): 454 - 462
    01/15/2013 Authors: Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
  • SPARC and DNA methylation: possible diagnostic and therapeutic implications in gastrointestinal cancers.
    Cancer Lett Volume: 328 Page(s): 10 - 17
    01/01/2013 Authors: Nagaraju GP; El-Rayes BF
  • Tools to optimize the functionality of a leukemia clinical trial team.
    Leuk Lymphoma Volume: 54 Page(s): 110 - 116
    01/01/2013 Authors: Bethelmie-Bryan B; Lord K; Holloway S; Safavi F; Shepard M; Rogers S; Harvey RD; Rodger K; Waller EK; El-Rayes B
  • A Loss of Function Genetic Screen Identifies Determinants of Sensitivity to PARP Inhibitor ABT-888 in Pancreatic Cancer
    Volume: 84 Page(s): S325 - S325
    11/01/2012 Authors: Park W; Pantazides BG; El-Rayes BF; Shelton JW; Yu DS
  • A Synthetic Lethal Screen Identifies Genes That Mediate Gemcitabine Resistance in Pancreatic Cancer
    Volume: 84 Page(s): S88 - S88
    11/01/2012 Authors: Pantazides B; Hardy C; Gandhi K; Landry J; Shelton J; Maithel S; El-Rayes B; Kowalski J; Yu D
  • Ganetespib, an HSP90 Inhibitor, Sensitizes Colorectal Cancers to the Effects of Ionizing Radiation
    Volume: 84 Page(s): S696 - S697
    11/01/2012 Authors: Diaz R; Nagaraju GP; Park W; El-Rayes BF; Landry JC
  • Salvage Yttrium-90 Radioembolization after Failed Chemotherapy for Colorectal Cancer Liver Metastases
    Volume: 56 Page(s): 842A - 843A
    10/01/2012 Authors: Lawal TO; Prajapati HJ; El-Rayes BF; Kauh JS; Kim HS
  • Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization.
    J Vasc Interv Radiol Volume: 23 Page(s): 1286 - 93.e1
    10/01/2012 Authors: Prajapati HJ; Rafi S; El-Rayes BF; Kauh JS; Kooby DA; Kim HS
  • The impact of curcumin on breast cancer.
    Integr Biol (Camb) Volume: 4 Page(s): 996 - 1007
    09/01/2012 Authors: Nagaraju GP; Aliya S; Zafar SF; Basha R; Diaz R; El-Rayes BF
  • Oxaliplatin-induced hepatoportal sclerosis, portal hypertension, and variceal bleeding successfully treated with transjugular intrahepatic portosystemic shunt.
    Clin Colorectal Cancer Volume: 11 Page(s): 224 - 227
    09/01/2012 Authors: Lawal TO; Farris AB; El-Rayes BF; Subramanian RM; Kim HS
  • Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma.
    Anticancer Res Volume: 32 Page(s): 3559 - 3563
    08/01/2012 Authors: Almhanna K; El-Rayes B; Sethi S; Dyson G; Heilbrun L; Philip PA; Sarkar F
  • Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.
    Expert Opin Ther Targets Volume: 16 Page(s): 707 - 718
    07/01/2012 Authors: Zafar SF; Nagaraju GP; El-Rayes B
  • Neuroendocrine tumors (NET) of the gastrointestinal tract: Experience at Winship Cancer Institute of Emory University
    Volume: 30
    05/20/2012 Authors: Zafar SF; Patil DH; Kauh JS; Adsay V; Kooby DA; Brutcher E; Maithel SK; El-Rayes BF
  • Safety and efficacy of modified FOLFIRINOX in pancreatic cancer: A retrospective experience
    Volume: 30
    05/20/2012 Authors: Mahaseth H; Kauh JS; Brutcher E; Hawk NN; Kim S; Chen Z; El-Rayes BF
  • Novel methods of analyzing long-term trends in incidence and survival applied to gastroesophageal cancers
    Volume: 30
    05/20/2012 Authors: Wang Z; Goodman M; Mahaseth H; El-Rayes BF
  • A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.
    Volume: 30
    05/20/2012 Authors: Owonikoko TK; Harvey RD; Kauh JS; Lewis CM; Hossain MS; Akintayo AO; Merriewether AR; Chen Z; Hawk NN; Saba NF
  • A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies
    Volume: 30
    05/20/2012 Authors: Kauh JS; Harvey RD; Owonikoko TK; El-Rayes BF; Shin DM; Murali S; Lewis CM; Karol MD; Teofilovici F; Du Y
  • A comparative analysis of locoregional therapy (hyperthermic intraperitoneal chemotherapy [HIPEC]) and systemic chemotherapy (CT) following cytoreductive surgery in patients (pts) with disseminated mucinous appendiceal cancers (MACA).
    Volume: 30
    05/20/2012 Authors: Bekaii-Saab TS; Martin LK; Vallabhaneni GD; Park W; Staley CA; Maithel SK; Wang Z; Chen Z; El-Rayes BF
  • Survival outcomes of patients with unresectable hepatocellular carcinoma in a national population-based study: SEER versus tertiary cancer center
    Volume: 30
    05/20/2012 Authors: Lawal TO; El-Rayes BF; Kim HS
  • A synthetic lethal screen identifies genetic determinants for gemcitabine sensitivity in pancreatic cancer
    CANCER RESEARCH Volume: 72
    04/15/2012 Authors: Landry JC; Pantazides BG; Park W; Shelton JW; Maithel SK; El-Rayes B; Yu DS
  • Antiangiogenic effects associated with the inhibition of HSP90 in colorectal cancer
    CANCER RESEARCH Volume: 72
    04/15/2012 Authors: Mahaseth H; Nagaraju GP; Diaz R; Taliaferro-Smith LD; Landry JC; Saba NF; El-Rayes BF
  • Potent curcumin analogues inhibit pancreatic cancer cell growth and angiogenesis
    CANCER RESEARCH Volume: 72
    04/15/2012 Authors: Nagaraju GP; Zhu S; Diaz R; Shoji M; El-Rayes BF
  • Functional inhibition of HSP90 potentiates the effects of ionizing radiation in colorectal cancer
    CANCER RESEARCH Volume: 72
    04/15/2012 Authors: Nagaraju GP; Wen J; El-Rayes BF; Landry JC; Park W; Diaz R
  • An analysis of ERCC1, hENT1, RRM1, and RRM2 expression in resected pancreas adenocarcinoma: Implications for adjuvant treatment.
    J Clin Oncol Volume: 30 Page(s): 206
    02/01/2012 Authors: Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay V; Maithel SK
  • An Analysis of ERCC1, hENT1, RRM1, and RRM2 Expression in Intrahepatic vs Extrahepatic Biliary Tract Malignancy: Implications for Treatment?
    Volume: 19 Page(s): S53 - S53
    02/01/2012 Authors: Fisher SB; Fisher KE; Patel SH; El-Rayes BF; Staley CA; Kooby DA; Adsay N; Farris AB; Maithel SK
  • An analysis of ERCC1, hENT1, RRM1, and RRM2 expression in resected pancreas adenocarcinoma: Implications for adjuvant treatment.
    Volume: 30
    02/01/2012 Authors: Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay V; Maithel SK
  • Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors.
    Chemother Res Pract Volume: 2012 Page(s): 291421
    01/01/2012 Authors: Saba NF; Yom SS; Haigentz M; El-Rayes B
  • Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma.
    Ann Surg Oncol Volume: 18 Page(s): 3384 - 3390
    11/01/2011 Authors: Patel SH; Kneuertz PJ; Delgado M; Kooby DA; Staley CA; El-Rayes BF; Kauh JS; Sarmiento JM; Hanish S; Cohen C
  • MAGNETIC RESONANCE IMAGING PREDICTS SURVIVAL AFTER DOXORUBICIN DRUG ELUTING BEADS CHEMOEMBOLIZATION IN UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Volume: 54 Page(s): 900A - 901A
    10/01/2011 Authors: Prajapati HJ; Spivey J; Hanish SI; Cherr Z; El-Rayes BF; Kauh JS; Kim HS
  • Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.
    Ann Surg Oncol Volume: 18 Page(s): 2699 - 2705
    09/01/2011 Authors: Maithel SK; Coban I; Kneuertz PJ; Kooby DA; El-Rayes BF; Kauh JS; Sarmiento J; Staley CA; Volkan Adsay N
  • A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.
    Invest New Drugs Volume: 29 Page(s): 694 - 699
    08/01/2011 Authors: El-Rayes BF; Philip PA; Sarkar FH; Shields AF; Ferris AM; Hess K; Kaseb AO; Javle MM; Varadhachary GR; Wolff RA
  • Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U. S. experience
    JOURNAL OF CLINICAL ONCOLOGY Volume: 29
    05/20/2011 Authors: Smyth EC; Enzinger PC; Li J; Vincitore M; Lacy J; El-Rayes BF; Kunz PL; Ford JM; Robinson E; Kelsen DP
  • Survival outcomes of nonoperative therapy (NOT) alone versus NOT followed by surgery (NOTS) in patients with esophageal cancer (EC): SEER analysis 2000-2007.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 29
    05/20/2011 Authors: Saba NF; Kim HM; El-Rayes BF; Kono SA; Ramalingam SS; Owonikoko TK; Landry JC; Miller DL; Shin DM; Khuri FR
  • CA19-9 for the prediction of efficacy of chemotherapy in patients with advanced pancreas cancer: A pooled analysis of six prospective trials.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 29
    05/20/2011 Authors: Bauer TM; Bekaii-Saab TS; Li X; Villalona-Calero MA; Philip PA; Shields AF; Zalupski MM; Hammad N; El-Rayes BF
  • Survival outcomes of nonoperative therapy (NOT) alone versus NOT followed by surgery (NOTS) in patients with esophageal cancer (EC): SEER analysis 2000-2007.
    J Clin Oncol Volume: 29 Page(s): e14569
    05/20/2011 Authors: Saba NF; Kim HM; El-Rayes BF; Kono SA; Ramalingam SS; Owonikoko TK; Landry JC; Miller DL; Shin DM; Khuri FR
  • Squamous cell cancer of the anal canal in HIV-infected patients receiving highly active antiretroviral therapy: a single institution experience.
    Am J Clin Oncol Volume: 34 Page(s): 135 - 139
    04/01/2011 Authors: Hammad N; Heilbrun LK; Gupta S; Tageja N; Philip PA; Shields AF; Smith D; El-Rayes BF
  • Clinicopathological analysis of primary epithelial appendiceal neoplasms.
    Med Oncol Volume: 27 Page(s): 1073 - 1078
    12/01/2010 Authors: Gupta S; Parsa V; Adsay V; Heilbrun LK; Smith D; Shields AF; Weaver D; Philip PA; El-Rayes BF
  • Impact of race, age, and socioeconomic status on participation in pancreatic cancer clinical trials.
    Pancreas Volume: 39 Page(s): 967 - 971
    10/01/2010 Authors: El-Rayes BF; Jasti P; Severson RK; Almhanna K; Philip PA; Shields A; Zalupski M; Heilbrun LK
  • A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.
    Ann Oncol Volume: 21 Page(s): 1999 - 2004
    10/01/2010 Authors: El-Rayes BF; Zalupski M; Bekai-Saab T; Heilbrun LK; Hammad N; Patel B; Urba S; Shields AF; Vaishampayan U; Dawson S
  • MULTIVARIATE SURVIVAL ANALYSIS OF PREDICTIVE FACTORS OF HEPATOCELLULAR CARCINOMA TREATED WITH DOXORUBICIN DRUG ELUTING BEADS TRANSCATHETER CHEMOEMBOLIZATION
    Volume: 52 Page(s): 1165A - 1166A
    10/01/2010 Authors: Dhanasekaran R; Rafi S; El-Rayes BF; Kauh JS; Kooby DA; Kim HS
  • CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.
    Asia Pac J Clin Oncol Volume: 6 Page(s): 98 - 105
    06/01/2010 Authors: Hammad N; Heilbrun LK; Philip PA; Shields AF; Zalupski MM; Venkatramanamoorthy R; El-Rayes BF
  • Chemoembolization with doxorubicin drug-eluting beads for unresectable hepatocelluar carcinoma with portal vein thrombosis
    JOURNAL OF CLINICAL ONCOLOGY Volume: 28
    05/20/2010 Authors: McIntosh EB; Dhanasekaran R; Kauh JS; El-Rayes BF; Kooby DA; Williams RS; Kim HS
  • Long-term survival after locoregional therapy in patients with unresectable hepatocellular carcinoma: Improvements over two decades.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 28
    05/20/2010 Authors: Dhanasekaran R; McIntosh EB; Kauh JS; Kooby DA; El-Rayes BF; Kim HS
  • Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 28
    05/20/2010 Authors: Kauh JS; Harvey RD; Lawson DH; Owonikoko TK; Tighiouart M; Ramalingam SS; Shin DM; Lewis CM; El-Rayes BF; Khuri FR
  • Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
    J Cell Biochem Volume: 110 Page(s): 171 - 181
    05/01/2010 Authors: Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
  • Dedifferentiated Goblet Cell Carcinoid (Adenocarcinoma Ex GCC) Is a Morphologically Distinctive and Aggressive Neoplasm with Peritoneal Dissemination: An Analysis of 35 Cases
    Volume: 90 Page(s): 137A - 137A
    02/01/2010 Authors: Basturk O; Cheng J; Philip P; El-Rayes B; Coban I; Bandyopadhyay S; Cuhaci N; Adsay NV
  • Dedifferentiated Goblet Cell Carcinoid (Adenocarcinoma Ex GCC) Is a Morphologically Distinctive and Aggressive Neoplasm with Peritoneal Dissemination: An Analysis of 35 Cases
    Volume: 23 Page(s): 137A - 137A
    02/01/2010 Authors: Basturk O; Cheng J; Philip P; El-Rayes B; Coban I; Bandyopadhyay S; Cuhaci N; Adsay NV
  • Concurrent Inhibition of NF kappa B, Cyclooxygenase-2 and Epidermal Growth Factor Toward Pancreatic Cancer Therapy
    PANCREAS Volume: 38 Page(s): 981 - 981
    11/01/2009 Authors: Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
  • Protein kinases C isozymes are differentially expressed in human breast carcinomas.
    Life Sci Volume: 84 Page(s): 766 - 771
    05/22/2009 Authors: Ali S; Al-Sukhun S; El-Rayes BF; Sarkar FH; Heilbrun LK; Philip PA
  • A retrospective review of squamous cell carcinoma of the anal canal in HIV-positive and HIV-negative patients
    Volume: 27
    05/20/2009 Authors: Hammad N; Philip PA; Shields AF; Heilbrun LK; Venkatramanamoorthy R; El-Rayes BF
  • (18)F-Fluorodeoxyglucose positron emission tomography (FDG-PET) as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC).
    J Clin Oncol Volume: 27 Page(s): e15037
    05/20/2009 Authors: Philip PA; Gupta S; Heilbrun L; Smith D; El-Rayes B; Shields A
  • F-18-Fluorodeoxyglucose positron emission tomography (FDG-PET) as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC)
    Volume: 27
    05/20/2009 Authors: Philip PA; Gupta S; Heilbrun L; Smith D; El-Rayes B; Shields A
  • A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer
    Volume: 27
    05/20/2009 Authors: El-Rayes BF; Patel B; Zalupski M; Hammad N; Shields A; Heilbrun L; Venkatramanamoorthy R; Philip P
  • Exploitation of protein kinase C: a useful target for cancer therapy.
    Cancer Treat Rev Volume: 35 Page(s): 1 - 8
    02/01/2009 Authors: Ali AS; Ali S; El-Rayes BF; Philip PA; Sarkar FH
  • Ritonavir mediated protection of retinoblastoma-E2F-1 complex at G1 phase of cell cycle in pancreatic cancer cell lines
    Volume: 207 Page(s): S97 - S97
    09/01/2008 Authors: Batchu RB; Prasad M; Steffes C; Shammas M; El-Rayes BF; Weaver DW
  • Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.
    Mol Cancer Ther Volume: 7 Page(s): 1708 - 1719
    06/01/2008 Authors: Ali S; Banerjee S; Ahmad A; El-Rayes BF; Philip PA; Sarkar FH
  • A phase II study of isoflavone, gemcitabine, and erlotinib in locally advanced (LA) or metastatic pancreatic cancer
    JOURNAL OF CLINICAL ONCOLOGY Volume: 26
    05/20/2008 Authors: Hammad N; Philip PA; Shields AF; Sarkar FH; Abruzzese JL; Kaseb AO; Javle MM; Varadhachary GR; Wolff RA; El-Rayes BF
  • A comparison of advanced pancreatic cancer patients treated on clinical trials with those from a SEER registry over an 18 year period
    JOURNAL OF CLINICAL ONCOLOGY Volume: 26
    05/20/2008 Authors: Jasti P; El-Rayes BF; Heilbrun LK; Philip PA; Zalupski MM; Shields AF; Venkatramanamoorthy R; Severson R
  • A phase II study of bevacizumab, docetaxel and oxaliplatin in gastric and gastroesophageal junction (GEJ) cancer
    JOURNAL OF CLINICAL ONCOLOGY Volume: 26
    05/20/2008 Authors: El-Rayes BF; Hammad N; Philip PA; Shields AF; Heilbrun LK
  • Protein kinase C: a target for therapy in pancreatic cancer.
    Pancreas Volume: 36 Page(s): 346 - 352
    05/01/2008 Authors: El-Rayes BF; Ali S; Philip PA; Sarkar FH
  • Ritonavir, a protease inhibitor, induces apoptosis in pancreatic cancer cells by inhibiting the AKT signaling pathway
    GASTROENTEROLOGY Volume: 134 Page(s): A740 - A740
    04/01/2008 Authors: Bryant CS; Kumar S; El-Rayes B; Qazi A; Steffes CP; Prasad M; Weaver DW; Shammas MA; Batchu RB
  • Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
    Cancer Chemother Pharmacol Volume: 61 Page(s): 283 - 289
    02/01/2008 Authors: El-Rayes BF; Zalupski MM; Manza SG; Rusin B; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Shields AF; Philip PA
  • Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
    Cancer Volume: 110 Page(s): 770 - 775
    08/15/2007 Authors: Schneider BJ; El-Rayes B; Muler JH; Philip PA; Kalemkerian GP; Griffith KA; Zalupski MM
  • A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer.
    Am J Clin Oncol Volume: 30 Page(s): 340 - 345
    08/01/2007 Authors: Desai SP; El-Rayes BF; Ben-Josef E; Greenson JK; Knol JA; Huang EH; Griffith KA; Philip PA; McGinn CJ; Zalupski MM
  • CA 19-9 as a predictor of response and survival in patients with pancreatic cancer treated with gemcitabine and cisplatin based chemotherapy
    Volume: 25
    06/20/2007 Authors: Heilbrun LK; Khanna A; Venkatramanamoorthy R; Shields AF; Philip PA; Zalupski MM; El-Rayes BF
  • A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin.
    Am J Clin Oncol Volume: 30 Page(s): 101 - 105
    04/01/2007 Authors: El-Rayes BF; Zalupski M; Shields AF; Manza SG; LoRusso P; Philip PA
  • Phase I study of bryostatin 1 and gemcitabine.
    Clin Cancer Res Volume: 12 Page(s): 7059 - 7062
    12/01/2006 Authors: El-Rayes BF; Gadgeel S; Shields AF; Manza S; Lorusso P; Philip PA
  • Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.
    Cancer Res Volume: 66 Page(s): 10553 - 10559
    11/01/2006 Authors: El-Rayes BF; Ali S; Ali IF; Philip PA; Abbruzzese J; Sarkar FH
  • A phase I study of flavopiridol and docetaxel.
    Invest New Drugs Volume: 24 Page(s): 305 - 310
    07/01/2006 Authors: El-Rayes BF; Gadgeel S; Parchment R; Lorusso P; Philip PA
  • The role of venography in the evaluation of malfunctioning central venous access ports (CVAPs).
    J Clin Oncol Volume: 24 Page(s): 18535
    06/20/2006 Authors: Atallah E; Salomon M; Schiffer CA; El-Rayes B
  • A dose attenuated schedule of irinotecan and capecitabine in combination with celecoxib in advanced colorectal cancer.
    Volume: 24 Page(s): 166S - 166S
    06/20/2006 Authors: El-Rayes BF; Shields AF; Vaishampayan U; Heilbrun LK; Zalupski MM; Philip PA
  • A retrospective review of anal squamous cell carcinoma in HIV positive and HIV negative patients.
    Volume: 24 Page(s): 215S - 215S
    06/20/2006 Authors: Grandhi J; Philip PA; Washington T; Shields AF; Vaishampayan U; Heilburn LK; Venkatramanamoorthy R; El-Rayes BF
  • Phase II study of celecoxib, irinotecan, and capecitabine in patients with advanced colorectal cancer
    Volume: 17 Page(s): 70 - 70
    01/01/2006 Authors: El-Rayes B; Shields A; Zalupski M; Bekaii-Saab T; Heilbrun L; Vaishampayan U; Manza S
  • Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy.
    Mol Cancer Ther Volume: 4 Page(s): 1943 - 1951
    12/01/2005 Authors: Ali S; El-Rayes BF; Sarkar FH; Philip PA
  • A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
    Invest New Drugs Volume: 23 Page(s): 583 - 590
    12/01/2005 Authors: El-Rayes BF; Zalupski MM; Shields AF; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Adsay V; Philip PA
  • CA 19-9 as a predictor of response and survival in patients with pancreatic cancer treated with gemcitabine and cisplatin based chemotherapy.
    Volume: 23 Page(s): 355S - 355S
    06/01/2005 Authors: Patel B; Heilburn L; Khanna A; Venkatramanamoorthy R; Shields A; Philip P; Zalupski M; El-Rayes B
  • A phase II trial of celecoxib, irinotecan, and capecitabine in metastatic colorectal cancer.
    Volume: 23 Page(s): 290S - 290S
    06/01/2005 Authors: El-Rayes BF; Zalupski MM; Shields AF; Heilbrun LK; Bekaii-Saab T; Vaishampayan U; Philip PA
  • A phase II trial of carboplatin, gemcitabine and capecitabine in patients with carcinoma of unknown primary site (CUP).
    Volume: 23 Page(s): 330S - 330S
    06/01/2005 Authors: Schneider BJ; Muler J; Philip P; Kalemkerian G; El-Rayes B; Griffith K; Zalupski M
  • A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary.
    Am J Clin Oncol Volume: 28 Page(s): 152 - 156
    04/01/2005 Authors: El-Rayes BF; Shields AF; Zalupski M; Heilbrun LK; Jain V; Terry D; Ferris AM; Philip PA
  • Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells.
    Breast Cancer Res Treat Volume: 90 Page(s): 25 - 31
    03/01/2005 Authors: Ali S; El-Rayes BF; Aranha O; Sarkar FH; Philip PA
  • Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors.
    Invest New Drugs Volume: 23 Page(s): 57 - 62
    01/01/2005 Authors: El-Rayes BF; Ibrahim D; Shields AF; LoRusso PM; Zalupski MM; Philip PA
  • Cellular DNA content parameters as prognostic indicators in human astrocytomas.
    J Neurooncol Volume: 71 Page(s): 85 - 89
    01/01/2005 Authors: El-Rayes BF; Norton CS; Sakr W; Maciorowski Z; Smith D; Pietraszkiewicz H; Del Mar Alonso M; Ensley JF
  • Pseudoaneuploid subpopulations detected in normal upper aerodigestive tract mucosa consistent with physiological apoptosis in normally differentiating squamous mucosa.
    Otolaryngol Head Neck Surg Volume: 131 Page(s): 633 - 638
    11/01/2004 Authors: El-Rayes BF; Korkmaz H; Maciorowski Z; Sakr W; Jacobs JR; Ensley JF
  • Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.
    Mol Cancer Ther Volume: 3 Page(s): 1421 - 1426
    11/01/2004 Authors: El-Rayes BF; Ali S; Sarkar FH; Philip PA
  • Targeting the epidermal growth factor receptor.
    Br J Cancer Volume: 91 Page(s): 418 - 424
    08/02/2004 Authors: El-Rayes BF; LoRusso PM
  • Phase II study of capecitabine, irinotecan, and celecoxib in advanced colorectal cancer.
    Volume: 22 Page(s): 310S - 310S
    07/15/2004 Authors: El-Rayes BF; Shields AF; Vaishampayan U; Heilbrun L; Bekaii-Saab T; Zalupski MM; Philip PA
  • A phase II study of gemcitabine by fixed-dose rate infusion, cisplatin, and celecoxib in metastatic pancreatic cancer.
    Volume: 22 Page(s): 343S - 343S
    07/15/2004 Authors: Kobrossy B; El-Rayes BF; Shields AF; Vaishampayan U; Heilbrun L; Zalupski MM; Philip PA
  • Cytochrome p450 and glutathione transferase expression in squamous cell cancer.
    Clin Cancer Res Volume: 10 Page(s): 4412 - 4416
    07/01/2004 Authors: Ali S; El-Rayes BF; Heilbrun LK; Sarkar FH; Ensley JF; Kucuk O; Philip PA
  • A phase II study of carboplatin and paclitaxel in esophageal cancer.
    Ann Oncol Volume: 15 Page(s): 960 - 965
    06/01/2004 Authors: El-Rayes BF; Shields A; Zalupski M; Heilbrun LK; Jain V; Terry D; Ferris A; Philip PA
  • Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
    Int J Radiat Oncol Biol Phys Volume: 59 Page(s): 454 - 459
    06/01/2004 Authors: Ben-Josef E; Shields AF; Vaishampayan U; Vaitkevicius V; El-Rayes BF; McDermott P; Burmeister J; Bossenberger T; Philip PA
  • Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line.
    Pancreas Volume: 28 Page(s): e90 - e95
    05/01/2004 Authors: Li Y; Ellis K-L; Ali S; El-Rayes BF; Nedeljkovic-Kurepa A; Kucuk O; Philip PA; Sarkar FH
  • Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
    J Clin Oncol Volume: 21 Page(s): 2920 - 2925
    08/01/2003 Authors: El-Rayes BF; Zalupski MM; Shields AF; Vaishampayan U; Heilbrun LK; Jain V; Adsay V; Day J; Philip PA
  • Cytochrome p450 and glutathione transferase expression in human breast cancer.
    Clin Cancer Res Volume: 9 Page(s): 1705 - 1709
    05/01/2003 Authors: El-Rayes BF; Ali S; Heilbrun LK; Lababidi S; Bouwman D; Visscher D; Philip PA
  • Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
    Urology Volume: 61 Page(s): 774 - 780
    04/01/2003 Authors: Hussain M; Smith DC; El-Rayes BF; Du W; Vaishampayan U; Fontana J; Sakr W; Wood D
  • Hormone-refractory prostate cancer responding to capecitabine
    UROLOGY Volume: 61
    02/01/2003 Authors: El-Rayes BF; Black CA; Ensley JF
  • Unusual case of antiphospholipid antibody syndrome presenting with extensive cutaneous infarcts in a patient on long-term procainamide therapy.
    Am J Hematol Volume: 72 Page(s): 154
    02/01/2003 Authors: El-Rayes BF; Edelstein M
  • Comparison of DNA content parameters in paired, fresh tissue pretreatment biopsies and surgical resections from squamous cell carcinoma of the head and neck.
    Otolaryngol Head Neck Surg Volume: 128 Page(s): 169 - 177
    02/01/2003 Authors: El-Rayes BF; Maciorowski Z; Pietraszkiewicz H; Ensley JF
  • Hormone-refractory prostate cancer responding to capecitabine.
    Urology Volume: 61 Page(s): 462
    02/01/2003 Authors: El-Rayes BF; Black CA; Ensley JF
  • Developments in the systemic therapy of pancreatic cancer.
    Cancer Invest Volume: 21 Page(s): 73 - 86
    01/01/2003 Authors: el-Rayes BF; Shields AF; Vaitkevicius V; Philip PA
  • Vascular access thrombosis and hypercoagulable states in patients with end stage renal disease on hemodialsis.
    Volume: 100 Page(s): 270A - 270A
    11/16/2002 Authors: El-Rayes BF; Amm JMA; Sondheimer JH; Andersen JC
  • Breast cancer in women with human immunodeficiency virus infection: implications for diagnosis and therapy.
    Breast Cancer Res Treat Volume: 76 Page(s): 111 - 116
    11/01/2002 Authors: El-Rayes BF; Berenji K; Schuman P; Philip PA
  • Broad array of coagulation defects in patients with membranous nephropathy and minimal change disease.
    Volume: 13 Page(s): 676A - 676A
    09/01/2002 Authors: Amm JMA; El-Rayes BF; Andersen JC; Rossi NF
  • Vascular access thrombosis and hypercoagulable states.
    Volume: 13 Page(s): 713A - 713A
    09/01/2002 Authors: Amm JMA; El-Rayes BF; Andersen JC; Sondheimer JH
  • Systemic therapy for advanced pancreatic cancer.
    Expert Rev Anticancer Ther Volume: 2 Page(s): 426 - 436
    08/01/2002 Authors: El-Rayes BF; Philip PA
  • Ciprofloxacin inhibits cell growth and synergises the effect of etoposide in hormone resistant prostate cancer cells.
    Int J Oncol Volume: 21 Page(s): 207 - 211
    07/01/2002 Authors: El-Rayes BF; Grignon R; Aslam N; Aranha O; Sarkar FH
  • Hormonal therapy for prostate cancer: past, present and future.
    Expert Rev Anticancer Ther Volume: 2 Page(s): 37 - 47
    02/01/2002 Authors: el-Rayes BF; Hussain MH
  • Pancreatic cancer: the evolving role of systemic therapy.
    Expert Opin Pharmacother Volume: 2 Page(s): 1939 - 1947
    12/01/2001 Authors: Adsay NV; El-Rayes BF; Philip PA
  • Long term comparison of event free and overall survival in patients with non-Hodgkin's lymphoma (NHL) treated with autologous or allogeneic marrow/stem cell transplantation on a single protocol over a 12 year period.
    Volume: 98 Page(s): 680A - 680A
    11/16/2001 Authors: El-rayes BF; Abella E; Dansey R; Klein JL; Hamm C; Karanes C; Baynes RD
  • Traumatic war neurosis: Egyptian experience.
    J R Army Med Corps Volume: 128 Page(s): 67 - 71
    06/01/1982 Authors: El Sudany El Rayes BM
Read more publications Fewer publications
Directory
  • Faculty Profiles
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2025 Emory University
  • Privacy Policy
  • Emergency Information
  • EEO Employer-Disability/Veteran Statements